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ABSTRACT 
Title of the Study: Health-related quality of life (HRQoL) as predictor of 
medication adherence in patients infected with Human Immune-deficiency 
Virus (HIV). 
Summary: Quality of life (QoL) is a broad term which involves evaluation of 
all aspects of life including, health, education, family life, housing, friendship, 
marriage, standard of living, and work. Health is one of the domains that affect 
our quality of life. The measurement of HRQoL is becoming an increasingly 
common activity in healthcare systems around the world. Health-related quality 
of life or biological outcome of treatment might predict adherence to HIV 
medication. This research is aimed to study the effect of HRQoL on medication 
adherence in patients infected with HIV. The original study was funded by NIH 
and conducted by Dr. Cynthia Willey, at University of Rhode Island during the 
years 1995-98. The purpose of the original project was to assess the stages of 
changes for adherence with HIV-Related Medications. The sample consisted of 
145 patients. The questionnaire was developed by AIDS Clinical Trial Group 
(AACTG). Questionnaires were distributed to the patients in Rhode Island at 
different sites affiliated with Brown University AIDS program. These sites 
included: 
1. The Miriam Hospital Immunology Center: This center serves majority of 
the HIV positive women in Rhode Island. 
2. Stanley Street Treatment and Resources: This center serves the Greater 
Fall River Massachusetts area and provides care to indigent and 
intravenous drug users. 
3. Veteran Affairs Medical Center in Providence, Rl: This center treats 
approximately 60 HIV positive men. 
Methodology: The data was collected by administering a standardized self-
reported questionnaire to the subjects to assess the compliance to HIV drugs. 
The questionnaire covered various aspects like, Demographic, Economic status, 
Coping, Quality of life, Medication, etc. Four domains of health-related quality 
of life were measured using 12 questions based on SF-36 included in the 
questionnaire. Medication adherence was assessed as self-reported adherence 
and also using Medication Adherence Scale. Univariate and bivariate tests were 
run to check for confounding variables in the data set. Logistic regression was 
used to determine any interaction between independent variables. The effect of 
Quality of life domains on medication adherence were assessed by running 
logistic regression model after controlling for potential confounding factors. 
Results: The results of this study indicate that "vitality/fatigue" is significantly 
associated with 95% self-reported adherence in patients taking protease 
inhibitors. This study thus confirms that patients with better mental health are 
more likely to adhere to their medication regimen. This is consistent with 
previous findings by other researchers. No other meaningful association was 
found between any other domain of QoL and medication adherence. 
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INTRODUCTION 
Acquired Immunodeficiency Syndrome (AIDS) is a significant healthcare, social, and 
psychological problem facing the mankind. When AIDS emerged from the shadows 
two decades ago, few people could predict how the epidemic would evolve, and fewer 
still could describe the best ways of combating it. As we face the third decade of AIDS 
epidemic, the impact of this disease is enormous. Human immunodeficiency virus is a 
major public health problem in all parts of the world [1]. 
Worldwide, nearly 40 million people are living with human immunodeficiency virus 
(HIV), which causes AIDS [2]. These include 19 .6 million males, 17 .6 million 
females, and 2.7 million children (less than 15 years of age). Globally, AIDS is a 
fourth leading cause of death [3]. In United States alone, approximately 1 million 
people live with HIV infection [2]. HIV/AIDS has become one of the highest 
expenditure infections in terms of cost of treatment and care provided, lost 
productivity hours, and disability [ 1]. 
Mankind faces multiple challenges in fighting AIDS. Social stigma and discrimination 
are the major obstacles to effective HIV/AIDS prevention and care. Fear of 
discrimination may prevent people from seeking treatment for AIDS or from 
acknowledging their HIV status. 
Until quite recently, the disease was considered to carry an almost certain debilitating, 
downward course leading to early death from opportunistic infections. Not long ago, 
1 
zidovudine, a nucleoside analogue reverse transcriptase inhibitor, was the only drug 
used to treat HIV. This drug interferes with the actions of specific HIV enzyme 
involved in the replication of cycle of HIV. 
But, the treatment of HIV virus has changed immensely. With advances in HIV 
treatment regimens, HIV has become a treatable chronic illness that requires extensive 
clinical management [ 4]. New potent drugs are prolonging the lives of thousands of 
patients infected with HIV. There are now dozens of medications available to attack 
different enzymes in HIV virus lifecycles. These drugs can be classified into three 
categories depending on the enzymes they target in HIV lifecycle. These are: 
1. Nucleoside reverse transcriptase inhibitors (NRTI's) 
2. Non-nucleoside reverse transcriptase inhibitors. (NNRTI's) 
3. Protease inhibitors (PI's) 
Since the potential for mutation is very high with HIV, drugs are more effective when 
used in combination. Convergent therapy uses drugs from same class to target same 
enzyme, while divergent therapy used drugs from different class to target different 
enzymes. The combination of both convergent and divergent therapy is called highly 
active anti-retroviral therapy (HAART). The first of protease inhibitors were 
introduced in 1995. Since the late 1997, when HAART was first introduced, the 
combination of protease and reverse transcriptase inhibitors had proven effective in 
driving HIV viral loads to very low or undetectable levels [5] . The most commonly 
used combination includes one potent protease inhibitor and two NRTI' s. The impact 
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of protease inhibitor based combination therapy has resulted in astonishing 
improvements in survival [6]. The survival rates have increased with both longer 
AIDS free survival and lower mortality [7] . This shift to the use of HAART for 
treating HN has led to increasingly complex drug regimen [8] . Adherence has been 
often called the "Achilles' heel" of highly active anti-retroviral therapy. 
HAART is highly effective but the drugs have short half-lives and are highly selective, 
leading to drug resistant strains if therapeutic levels are not maintained [9]. The long-
term effectiveness of HAART is dependent upon achieving maximum and durable 
suppression of HN plasma viral load [9, 10]. Even in successfully suppressed 
patients, HN replication will rapidly rebound if HAART is discontinued. One of the 
major challenges to good adherence to HAART has been complexity of regimens. 
HIV medication regimens are complicated and require extensive time and effort from 
the patient [ 11]. Many drugs need to be taken three times a day and the pill burden is 
overwhelming i.e. 15 -20 pills daily. Some drugs need to be taken with food, some 
without food and still others with dietary supplements. The complexity of HAART 
regimen sometimes requires patients to change their eating and sleeping pattern. This 
level of lifestyle change and accommodation may result in frustration and treatment 
failure [12]. Non-adherence to HN treatment regimen is a primary cause of treatment 
failure now. As a result of the pivotal role that adherence plays in the success of 
HAART, a tremendous amount has been written emphasizing the importance of 
adherence [5]. 
3 
Adherence, often used interchangeably with compliance, is "an act, action, or quality 
of being consistent [13) with administration of prescribed medication". The term 
adherence is preferred over compliance because it affirms patient's active participation 
in choosing and maintaining a treatment regimen. The concept of adherence 
additionally extends beyond medication management, to encompass a comprehensive 
treatment plan. 
Adherence simply means how accurately patients take their medications. One hundred 
percent adherence to any medication regimen is not easy to achieve. One recent study 
on adherence behavior in HN has shown that only 55-62% of patients are highly 
adherent to their medication therapy [ 14]. Many factors have been shown to affect 
patient's adherence. 
Patient Factors and Health Beliefs: Demographic characteristics (like, age, gender, 
race, etc.) have not been consistently found to be predictive of adherence [15, 16). 
However, other factors like heavy alcohol use, drug abuse, and depression have been 
found to be associated with adherence [17, 18). Various aspects of patients' beliefs 
about the nature of their disease [11), perceived importance of medication used [12), 
the health care system, and cultural factors affect medication adherence. Patients who 
perceive that their disease is a "serious health problem" and believe that the prescribed 
medications are necessary are more likely to adhere to prescribed medication regimens 
[12). In general, increased knowledge about disease and purposes of therapies increase 
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adherence [11]. However, concerns regarding safety of the medication on long term 
and the medication side effects could decrease medication adherence. 
Disease Factors: Investigations have found little relationship between type of illness 
and level of adherence [ 16] . Patients experiencing extreme pain or who are 
symptomatic are more likely to be adherent to their medications than patients who are 
asymptomatic. Many patients interrupt or stop taking their medications when they are 
asymptomatic. 
Provider Factors: General satisfaction with medical care appears to have no bearing on 
adherence. However, patient's dissatisfaction and unfulfilled expectations with the 
treatment and the doctor results in low adherence rates [ 11, 19] . The quality of 
interaction between doctor and patient can have major influence on health outcomes. 
Provider-patient relationship, especially communication about chronic nature of 
disease, the need for regular therapy, the role of medications, and discussion of side 
effects improves patient adherence. Poor provider-patient communication is associated 
with poor adherence. Affordability of medication, insurance coverage, and cost of 
therapy is a barrier to achieving adherence. 
Treatment complexities: Adherence is poorer in patients treated with more complex 
regimens [11, 20]. It has also been shown that adherence normally decreases over time 
and with greater number of pills that one is required to take [ 11]. One study measuring 
compliance with inhaled medication in asthma showed that as medication dosing 
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became more frequent, the adherence decreased from 71 % twice a day to 18% four 
times a day [20]. Anticipatory fear of side effects and secondary effects of illness such 
as nausea and dizziness can also reduce patient adherence. 
Psychosocial Factors: Given the complexity of human behavior, multiple determinants 
including patient characteristics may affect medication adherence. Behavior associated 
with chaotic lifestyle, depression, alcohol and elicit drug use often reduce adherence 
[11]. Patients with positive adaptive coping have been found to be more adherent to 
their medications [21]. Other factors like, presence of stress, lack of motivation, 
pessimism, and depression appears to result in non-adherence. Patients having 
sufficient levels of practical, emotional, and cognitive social support show higher level 
of adherence [ 11, 22]. 
Adherence is an important factor to achieve best outcomes in RN disease 
management. Although it is not known how adherent patients have to be to achieve 
best results, but it is believed that more adherent the patients, the more likely he is to 
have best results. Strict adherence to medication regimen yields high success. As more 
emphasis is laid on maintaining low viral count in HIV-infected patients, adherence to 
medication regiment has become an important issue [23]. Sub-optimal patient 
adherence has been shown to be related to inadequate viral suppression [24], reduced 
exposure to anti-retroviral drugs [25], the emergence to viral resistance [26], and RN 
disease progression and mortality [26]. Since the virus has the ability to mutate rapidly 
in absence of drug, taking anti-retroviral medication exactly as prescribed is the key 
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for success of therapy. HAAR T is very effective but drugs have short half-life and are 
highly selective favoring drug-resistant strains if therapeutic levels are not maintained. 
The rate of virologic failure sharply increases when less than 95% of prescribed dose 
of drug is actually taken [17] . In addition to taking adequate prescribed medication, 
anti-retroviral and protease inhibitors need to be taken according to correct time-
schedule, and for several drugs, dietary prescription. For most HIV-infected 
individuals, the alternative to lifelong adherent therapy may be devastating 
complication, often resulting in death. 
Measuring Adherence: 
One problem of measuring adherence is the lack of a standard measurement [ 15]. The 
methods commonly used to measure adherence can be classified as direct or indirect 
methods. Direct methods include pill count, biological assay, and electronic 
monitoring method, whereas indirect methods use questionnaire, interviews, or diary 
to estimate self reported adherence. All these methods have their respective 
advantages and disadvantages as discussed below. 
Self-Reported Medication Adherence: This is one of the simplest methods used to 
measure adherence. Three main types of self reports have been used including 
surveys, interviews and diaries. These involve asking patients how often they took (or 
missed) their medications by use of variety of surveys. However, reports of non-
adherence could be more reliable than reports of adherence. For example, the AIDS 
Clinical Trials Groups survey asks patients how many medication doses they missed 
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during previous day, 2 days or, 4 days. Despite the ease of administration, the self 
reported adherence measure has several limitations. Investigations have revealed that 
patients tend to overstate the actual adherence [27]. The patients want to present 
socially acceptable responses. Even if the patients are truthful, there is no data to 
prove how long the patients can remember what doses were missed several days ago 
[27]. 
Pill Count: Many investigators use pill count as method of measuring adherence. The 
pill count is generally done by study personnel like nurse, physician or, other health 
care practitioner. Although pill count avoids the subjective evaluation of adherence 
and has been demonstrate to correlate more highly with electronically measured 
adherence [28], the proportion of doses measured by pill count often exceeds actual 
number of doses taken. This method has several other limitations. Patients may forget 
to bring the bottles to the pharmacy. Patents also 'pill dump' and dispose extra 
medication doses to appear more adherent [29]. 
Biological Assays: Biological markers and tracer compounds indicate patient 
compliance over an extended period [30]. Plasma levels of antiretroviral drugs provide 
unequivocal evidence that the medication has been taken. To assess adherence using 
this method, the time and dose of the medication must be noted. Also, repeated plasma 
levels need to be withdrawn from the patient to improve the sensitivity of the test. 
This measure also has some drawbacks. Firstly, plasma levels only measure adherence 
to a dose prior to the visit or sample drawn [31]. Also, studies in many disease states 
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have demonstrated, patients who are aware that they may have a clinical sample like 
blood drawn to measure adherence will be more likely to adhere to the dose 
immediately prior to the visit than to other doses [32] . Besides, the pharmacokinetics 
of many drugs, especially protease inhibitors, varies significantly from person to 
person [32]. 
Electronic Monitors: MEMS (Medication event monitoring system) and eDEM are 
two commercially available monitors to measure adherence [15]. These devices are 
fitted with special pill bottle caps equipped with electronic chip that records each time 
a patient opens the bottle. This method has various advantages over subjective and 
other measures. Over estimation of self-reported adherence and pill dumping can be 
detected by this method. Additionally, this method also provides the time and date the 
pill bottle was opened each time. However, the cost of these high-tech devices is a 
problem for some investigators. Moreover, patient may open the bottle but not ingest 
the medicine. Some patients make a cache of medicine to be taken at office. This may 
not be recorded by this measure. 
The Importance of Health-related Quality of Life: 
The term "quality of life" was first used in 1943, in a novel about working in aircraft 
factory. However, it became popular with social scientists in the 1970' s, as US cities 
and states tried to rate the "quality of life" they offered. World Health Organization 
(WHO) Quality of Life group defines quality of life as "an individual ' s perception of 
their positions in the life in context of the culture and value systems in which they live 
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and in relation to their goals, expectations, standards and concerns. Quality of life is an 
evaluation of all aspects of life including, health, education, family life, community, 
housing, friendship, marriage, nation, neighborhood, standard of living, and work. 
Some authors also add spiritual security to the list of domains affecting quality of life. 
Health is one of the domains that affect our quality of life. WHO defined health in its 
constitution as "The state of optimum, physical, mental, and social well-being, and not 
merely the absence of disease or infirmity." The term health-related quality of life 
(HRQoL) encompasses multiple dimensions, including physical functioning, 
psychological state, general health status, family situational interaction, social ability, 
and somatic sensation. 
The measurement of HRQoL is becoming an increasingly common activity m 
healthcare systems around the world. These measurements are taken for variety of 
reasons including, as indicators of population health status, outcome measures in 
clinical trials, in economic evaluation of new technologies, and in some ,cases, for 
individual patient management. There are two basic approaches to measuring HRQoL. 
The first involves use of generic instruments that measure broad aspects of HRQoL. 
These instruments are not designed to assess HRQoL relative to particular medical 
condition, but rather to provide a general sense of the effects of an illness. Medical 
outcomes study Short-Form Health Survey (SF-36) is an example of generic HRQoL 
instrument. It measures HRQoL along 8 different domains: physical functioning, role 
limitation due to physical problems, bodily pain, general health, vitality, social 
functioning, role limitation due to emotional problems, and mental health. It assesses 
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both physical and mental health scores of the individual and measures both positive 
and negative aspects of Physical and Mental Health [33]. 
Generic measures can be administered to different populations to examine the impact 
of various healthcare/therapeutic programs on HRQoL. These measures allow for 
comparisons of HRQoL across a variety of medical conditions. The major limitation 
of generic instruments is that may not be sensitive enough to detect subtle treatment 
effects specific to a particular disease. 
The second approach involves the use of instruments that are specific to a disease 
(e.g., osteoporosis), a population (e.g., the elderly), or clinical problem (e.g. , pain). 
These measures are more sensitive towards specific disease or population, and 
therefore to have greater relevance to practicing clinician. The Arthritis Impact 
Measurement Scale (AIMS) is an example of disease-specific instrument that 
measures HRQoL specific to arthritis. 
Information about Quality of life of patients gathered systematically and routinely 
directly before consultation could be integrated in complex medical decision-making 
process [34]. Health related quality of life has been shown to be related with patient 
satisfaction and the main determinants of the health service quality improvement [35]. 
Health-related quality of life or biologic outcome of treatment might predict adherence 
to HIV medication. The correlation between HRQoL and adherence is complex and 
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merits careful study [36]. Many authors have reported the impact of HRQoL on 
patient's ability to adhere to treatment. Quality of life (QoL) may be an important 
consideration in maximizing treatment consideration in Hepatitis patient [37]. Sub-
optimal patient adherence was shown to be related to inadequate viral suppression 
[38]. Previous research suggests that patients with higher symptoms (poor physical 
health) and depression are more likely to be non-adherent to medications [21, 39]. The 
patients with better quality of life, do feel better about themselves and world, and are 
more likely to be adherent. Research data also supports the belief that survival and 
biomedical outcomes increase when the patient's perception of the impact of treatment 
on quality oflife is taken into consideration [ 40]. 
Most Highly Active Anti-Retroviral Treatment (HAART) regnnens are far from 
convenient for patients. HAART may have negative impact on patient's quality of life 
[ 41]. Short-term and long-term toxicities frequently occur which may have negative 
impact on the patient's Health-related quality of life (HRQoL). In addition, need for 
strict adherence to substantial number of pills, rigid time schedule, and dietary 
prescription may interfere with patient's daily activity. In patients with symptomatic 
HIV infection or AIDS, opportunistic infection could significantly affect HRQoL. In 
addition, social stigma ,associated with the disease and associated pain caused 
interferes with patient's ability to perform daily activities. It is therefore assumed that 
most people infected with HIV I AIDS do not feel well and that disease has an effect on 
their quality of life. 
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METHODOLOGY 
Study Design: 
The original study was conducted by Dr Cynthia Willey, Professor, Department of 
Pharrnacoeconomics and Pharrnacoepidemiology, University of Rhode Island, during 
the year 1995-98. The purpose of the original study was to develop measure of stages 
of change for medication adherence. National Institute of Health (NIH) funded the 
study. This is a descriptive cross-sectional study of self-reported adherence to 
prescribed HN medication adherence. 
Sample Population: 
The sample consisted of 145 patients who responded to the survey. All individuals 
were infected with HIV and currently prescribed approved HN medication. The 
sample comprised 71 % males and 29% females . The patients were aged between the 
ages 24-57. Mean age was 39. The sample comprised 62% whites and 38% non-
whites. Average level of education was 12 years. 
Data Collection: 
The data was collected by administering a standardized self-reported questionnaire to 
the subjects to assess the compliance to HIV drugs. Questionnaires were distributed to 
the patients in Rhode Island at different sites affiliated with Brown University AIDS 
program. These sites include: 
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1. The Miriam Hospital Immunology Center: This center serves majority of the 
HIV positive women in Rhode Island. 
2. Stanley Street Treatment and Resources: This center serves the Greater Fall 
River Massachusetts area and provides care to indigent and intravenous drug 
users. 
3. Veteran Affairs Medical Center in Providence, RI: This center treats 
approximately 60 HIV positive men. 
The questionnaire covered following aspects: 
• 
• 
Demographic: Age, gender, ethnicity, years of education, living status, and 
employment status. 
Economic status: Family income, job, type of health insurance coverage, and 
cost of treatment. 
• Coping: ways of coping with HIV. 
• Social support: Social, financial and emotional support provided by family and 
friends. 
• Quality of Life: Physical and mental functioning, general health, number of 
days spend in hospital in past two weeks, social ability and psychological 
health (as measured by SF-36). 
• Medication used: Adherence levels, number of doses missed in past one month 
and three months, side effects, etc. 
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Measure of Health-related Quality of Life: 
HRQoL is generally measured with a collection items, scales and domains. An item is 
a single question in an instrument. A domain identifies a particular focus of attention, 
like bodily pain, vitality, etc. SF-36 is a reliable, precise, and validated method of 
measuring quality of life [33, 42]. There is a strong basis for interpreting SF-36 scales 
as measure of health and health-related quality of life. A positive correlation (ranging 
from 0.43 to 0.69) has been found between SF-36 scales and general measure of 
quality of life [33]. The four domains of physical and mental health were measured for 
the purpose of this study. This enabled the production of scores with the same 
reliability and validity as those reported here and in other Medical Outcome Studies. 
Following set of questions were used to measure four domains of physical and mental 
health. 
Physical Health: 
Two domains of physical health were assessed by using the responses to the following 
questions. 
1. General Health Status: 
Q 1. How would you describe your current health status? 
2. Bodily Pain: 
Q 1. How much bodily pam have you had during the past four weeks? 
Q2. During the past 4 weeks, how much did pain interferes with your normal work 
(including both work outside the home and housework)? 
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Mental Health: 
Two domains of mental health were assessed by using the responses to the following 
questions. 
1. General Mental Health: 
Q 1. During the past 4 weeks, have you been a very nervous person? 
Q2. During the past 4 weeks, have you felt so down in dumps that nothing could 
cheer you up? 
Q3. During the past 4 week, have you been a happy person? 
Q4. During the past 4 weeks, have you felt downhearted and blue? 
Q5. During the past 4 weeks, have you felt calm and peaceful? 
2. Vitality/Fatigue: 
Q 1. During the past 4 weeks, did you have a lot of energy? 
Q2. During the past 4 weeks, did you feel full of prep? 
Q3. During the past 4 weeks, did you feel worn out? 
Q4. During the past 4 weeks, did you feel tired? 
HRQoL scales are scored so that higher score indicates better health state. The scoring 
involves following steps: 
Data Entry: The responses to all these questions are based on Likert Scale. All the 
responses were key punched as coded in the questionnaire. The response options were 
coded as 1, 2, 3, 4, and 5. 
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( Item Recoding: All questions were checked for out of range values. All out of range 
values were recoded as missing data. The next step after data entry was the recoding 
of response choices so that a higher score indicates a better health state. Hereby, 
question 
#1 to 4 in Mental health and question #3 to 4 were reverse coded so that higher score 
indicates better health. 
Item Recalibration: Two questions require recalibration to satisfy linear relationship 
between item scores (John ware et al, SF-36 health survey, manual and interpretation 
guide). 
General health: The responses were recoded as suggested in SF-36 scoring manual. 
Precoded item Value 
1 
2 
3 
4 
5 
Final Item value 
5.0 
4.4 
3.4 
2.0 
1.0 
Bodily Pain: The recommended recoding for two questions pertaining to bodily pain 
was followed. The administration of second question depends on the response to first 
question. The two questions in bodily pain had unequal number of response choices. 
This recoding method helped to convert second question to a six-level item of roughly 
equal variance to first question. 
Computing Raw Scores: After item recoding, raw scores were computed for each four 
scales i.e. General health, Bodily pain, vitality, and Mental Health individually. The 
raw score is the algebric sum of responses for all items in that scale. For example, the 
raw scale score for the mental health scale is the sum of the scores for all five 
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responses pertaining to general mental health. As recommended, if any respondent has 
missed more than one question on any domain, the score for that domain was not 
calculated. Finally each raw score was transformed to a 0 to 100 scale using the 
formula shown below. 
Transformed Score= [CActual raw score - lowest possible raw score)] *100 
Possible raw score range 
This transformation converts the lowest and highest possible scores to zero and 100, 
respectively. This transformation enables comparison of scores with norms derived 
from national health surveys and other published and forthcoming results. The scores 
were calculated separately for anti-retroviral and protease inhibitors drugs for the ease 
in analysis. 
Measure of Adherence: 
1. Percentage Adherence: 
Percentage adherence was calculated separately for anti-retroviral drugs and protease 
inhibitors. Percentage adherence in past three months was calculated using two sets of 
questions from the questionnaire. The number of doses missed was determined by 
using the response to question, "During the past three months, about how many times 
did you miss a dose of this medication"? The response to question, "How often do you 
take this medication" was used to determine the total number of doses the patient is 
supposed to take in three month period. 
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Percentage adherence was calculated by dividing total number of doses missed in the 
past three month by the total number of prescribed doses using the formula: 
Percentage adherence = 1- [ Number of doses missed in past three months ] x 100 
Total number of doses in three months 
The questionnaire has separate questions for different class of drugs, thus percentage 
adherence was calculated separately for anti-retroviral and protease inhibitors drugs. 
The average percentage adherence for the past three months was calculated for both 
anti-retroviral and protease inhibitors. 
No measure of adherence is perfect, and self-reported measures like questionnaires, 
often present the disadvantage of over reporting [ 43]. Although most literature 
suggests a cut-off limit of 80% in chronic conditions, successful HN therapy requires 
higher level of adherence. The rate of virologic failure sharply increases when less 
than 95% of prescribed dose of drug is actually taken [17] . Thus, a cut-off limit of 
95% adherence was selected to dichotomize respondents. All patients showing greater 
than or equal to 95% adherence were classified as "adherent" and those showing less 
than 95% adherence were classified as "non-adherent". The adherents were coded as 
"l" and non-adherents were coded as "O". 
2. Medication adherence scale: This is a previously validated scale to measure 
compliance. It contains six questions that are answered yes or no. Positive response 
indicates less medication adherence. A "Yes" was recoded as "l" and a ''No" was 
recoded as "2". The aggregate score for each respondent was obtained by taking the 
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sum of all six responses. The aggregate score ranged from 6 to 12 with higher score 
indicating poor adherence. This scale includes following questions: 
• During the last 3 months, have you ever stopped taking your protease 
inhibitor/antiretroviral medication because you felt worse? 
• During the last 3 months, have you ever forgotten to take your protease 
inhibitor/ antiretroviral medication? 
• During the last 3 months, have you at times been careless about taking your 
protease inhibitor/antiretroviral medication? 
• During the last 3 months, have you ever taken less of your protease 
inhibitor/antiretroviral medication than your doctor prescribed because you felt 
better? 
• During the last 3 months, have you ever taken less of your protease 
inhibitor/antiretroviral medication than your doctor prescribed because you felt 
worse? 
• Since you began taking protease inhibitors/antiretroviral medications, have you 
ever purposely taken more/less of the medication than your physician 
prescribed or discontinued your medications? 
The MAS scores were calculated separately for Anti-retroviral and protease inhibitor 
drugs. The MAS score was not calculated (coded as missing) if any respondent has 
missed more than one question in six item scale. Also, the average score of anti-
retroviral and protease inhibitors were individually calculated. Respondents with a 
score of 6 were classified as "adherent" and respondents with a score of more than 6 
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were classified as "non-adherent". Thus any respondent who has marked "yes" to at 
least one of the six questions was classified as non-adherent. This rather strict cut-off 
level of adherence was selected to offset over-reporting of adherence in self-reported 
measure. 
Statistical Analysis: 
Dependent Variable: 
• Adherence to anti-retroviral drugs in the past three months (dichotomous with 
95% cut-off level). 
• Adherence to protease inhibitors in the past three months (dichotomous with 
95% cut-off level) 
• 
• 
Adherence as measured using MAS for anti-retroviral drugs 
Adherence as determined using MAS for protease inhibitors . 
Independent Variable: On the basis of literature review, these variables were included 
in this research. The IVs of primary interest were-
• Bodily Pain 
• General Health 
• Mental Health 
• Vitality/Fatigue 
Demographic variable: 
• Age (Categorical variable ) 
< 35 years= 1 
2: 35 and< 42 years= 2 
:=:: 42 years= 3 
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• Gender (Categorical variable) 
Male= 1 
Female= 0 
• Ethnicity (Categorical variable) 
Whites= 1 
Non-whites= 0 
• Years of Education (Categorical variable) 
::::_ 12 years= 1 
< 12 years= 0 
• IV Drug use (Categorical variable) 
Occasionally to regular= 1 
Not at all or twice in 6 months= 0 
• CD4 count (Categorical variable) 
::: 200= 1 
> 200= 0 
• Time since Diagnosis (Categorical variable) 
Less than 1 month to 2 years= 1 
3 to 4 years= 2 
5 years or more= 3 
• Insurance (Categorical variable) 
Insured= 1 
Uninsured= 0 
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• Annual income (Categorical variable) 
< $15000= 1 
~ $15000= 0 
Of these, four domains of QoL are the N s of primary interest. The other variables 
may act as confounders. Univariate analyses were run on all dependent and 
independent variables. The data was tested for normality, linearity, skewness, and 
homoscedasticity. The primary independent variables were categorized into four 
categories and logistic regression was run between each independent variables and 
each dependent variable to assess parametric form. No linear relation was found 
between independent variable and dependent variable. The primary independent 
variables were thus categorized into two or three categories for the final model. 
Bivariate tests were run between dependent variables and all independent variables 
excluding variables of primary interest. Similar bivariate test were also run between 
primary independent variables and other independent variables. These include: 
1. Chi-square tests were performed between dependent variable i.e. 95% AV, 95% 
PI, MAS AV and MAS PI; and other independent variables like, age groups, 
gender, race, annual family income, years of education, time since diagnosis, 
CD4 count, injection drug use, and insurance. 
2. Chi-square tests were performed between each primary independent variable i.e. 
GH, BP, V, and MH; and other independent variables like, age, gender, race, 
annual family income, years of education, time since diagnosis, CD4 count, 
injection drug use, and insurance. 
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All categorical variables, which had more than two categories, were dummy coded 
for purpose of final logistic model for e.g. The primary independent variable "mental 
health" was dummy coded as Low MR-score below 28, Med MR-score between 28 
and 40. Patients with MR score more than 40 were treated as reference group. Test 
for collinearity was performed between each dependent variable and each 
independent variable. No collinearity was detected between any variables. Logistic 
model were run between each dependent variable and each independent variable. A 
maximum Likelihood ratio test (Chunk test) was performed to assess the 
significance of interaction terms in the model. The full model with all interaction 
terms and reduced model without interaction terms were compared for its log 
likelihood values. Any significant change in value suggested interaction in the 
model. 
The confounding effect of each independent variable was assessed as described by 
David Kleinbaum. Starting with the "Gold model" i.e. model with all independent 
variables, each variable was sequentially dropped with replacement and its effect on 
the odds ratio and confidence interval was studied. The variables which did not have 
any effect on the odds ratio were dropped from the model. Separate models were run 
for each primary independent variables due to high correlation between them. 
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RESULTS 
Table 1: Demographics and Clinical Characteristics of Patient Population on 
Anti-retroviral Medication: 
Total number of patients on anti-retroviral medication was 137. Age of these patients 
was between 24 and 57. The mean age was 38. Males constituted 73.0% of the sample 
while females constituted 26.9% of the sample. Majority of the patients were whites. 
Native Americans, Hispanics, Asians, African-American, and others together 
constituted 35.8% of the population. 
Majority of respondents had at least 12 years of education. About 29.0% of the 
patients reported that they lived alone while majority of them (70.9%) reported living 
with others. 60.5% reported that their annual income was more than $15,000. Majority 
of patients also had some kind of insurance, while only 16.0% of patients had no 
insurance. 64.6% of the patients had been diagnosed of HN for more than 5 years. 
47.6% had a T-cell count of less than 200 and 52.3% of the patients had a T-cell count 
of more than 200. Surprisingly, only 3.8% of the patients reported that they used 
intravenous drugs, while the majority of patients denied use of intravenous drugs in 
past 6 months. 
Table 2: Demographics and Clinical Characteristics of Patient Population on 
Protease-inhibitor Medication: 
Total number of patients on anti-retroviral medication was 77. Age of these patients 
was between 24 and 57. The mean age was 38. Males constituted 74.3% of the sample 
while females constituted 25.6% of the sample. Majority of the patients were whites. 
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Native Americans, Hispanics, Asians, African-American, and others together 
constituted only 22.9% of the population. 
Majority of respondents had at least 12 years of education. About 27.0% of the 
patients reported that they lived alone while majority of them (72.9%) reported living 
with others.57.3% reported that their annual income was more than $15,000. Majority 
of patients also had some kind of insurance, while only 12.1 % of patients had no 
insurance. 63.5% of the patients had been diagnosed of HIV for more than 5 years. 
54.9% had a T-cell count of less than 200 and 45 .1 % of the patients had a T-cell count 
of more than 200. Interestingly, only 2.6% of the patients reported that they used 
intravenous drugs, while the majority of patients denied use of intravenous drugs in 
past 6 months. 
Table 3: Adherence with Anti-retroviral (A.V.) Medications (Dependent 
Variable): 
Patients with adherence levels of more than 95% were classified as adherent, while 
patients with adherence level of less than 95% were classified as non-adherence. 
Using this cut-off, 87.7% (N= 115) of the patients were found to be adherent, while 
12.2% (N= 169) were found to be non-adherent. 
Medication Adherence Scale reported 42.2% (N= 62) being adherent, while 54.7% 
(N=75) reported not being adherent to their medication 
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Table 4: Adherence with Protease Inhibitor (P.I.) Medications (Dependent 
Variable) 
Patients with adherence levels of more than 95% were classified as adherent, while 
patients with adherence level of less than 95% were classified as non-adherence. 
Using this cut-off, 83.7% (N= 62) of the patients were found to be adherent, while 
16.2% (N= 12) were found to be non-adherent. 
Medication Adherence Scale showed that 48.0% (N= 37) have bee adherent, while 
51.9% (N=40) reported not being adherent to their medication 
Table 5: Mean and Range values of Quality of life domains (Primary IV) in 
patient on anti-retroviral drugs compared with general US population. 
As suggested in the literature, the patients scored significantly below the US general 
population on all four scales of Quality of life. This suggests lower physical as well as 
mental health reported by HN patients compared to US general population. 
Table 6: Mean and Range values of Quality of life domains (Primary IV) in 
patients on protease inhibitors compared with general US population. 
As suggested in the literature, the patients prescribed protease inhibitors scored 
significantly below the US general population on all four scales of Quality of life. This 
suggests lower physical as well as mental health reported by HN patients compared to 
US general population. 
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Table 7: Multiple Chi-Square Tests done on the Adherence to Antiretroviral 
Medications with 95% Cut off (Categorical Dependent Variable) and other 
Categorical Independent Variables. 
Chi square test showed no significant association between the adherence and other 
independent variables. This is consistent with past research that has shown that 
demographic variables are not associated with HN adherence. 
Table 8: Multiple Chi-Square Tests done on the Adherence to Antiretroviral 
Medications using MAS (Categorical Dependent Variable) and other Categorical 
Independent Variables. 
Chi square test showed no significant association between the adherence and other 
independent variables. This is consistent with past research that has shown that 
demographic variables are not associated with HN adherence. 
Table 9: Multiple Chi-Square Tests done on the Adherence to Protease Inhibitor 
Medications with 95% cut off (categorical Dependent Variable) and other 
Categorical Independent Variables. 
Chi square test showed no significant difference between the adherence and other 
independent variable except for variable "gender". Males were found to be more 
adherent than females . 
Table 10: Multiple Chi-Square Tests done on the Adherence to Protease 
Inhibitor Medications using MAS (categorical Dependent Variable) and other 
Categorical Independent Variables. 
The variable "annual family income", and "T-cell count" were found to be 
significantly associated with MAS adherence. Patients with annual income more than 
$15,000 were found to be more adherent than their poorer counterparts. Similarly, 
patients with T-cell count of less than 200 were found to be more adherent than 
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patients with T-cell count of more than 200. This is found to be consistent with 
previous research. 
Table. 11: Multiple Chi-Square tests done on "General Health" (Categorical) and 
other Independent Variables (Categorical) for people on anti-retroviral 
medication. 
The variable "ethnicity" and "annual family income" were found to be significantly 
associated with "general health". Whites reported better general health compared to 
non-whites. Similarly, patients with annual income greater than $15,000 had better 
mean score on general health compared to patients with annual income less than 
$15,000. 
Table. 12: Multiple Chi-Square tests done on "Bodily Pain" (Categorical) and 
other Independent Variables (Categorical) for people on anti-retroviral 
medication. 
The variable "ethnicity" was found to be significantly associated with "bodily pain". 
Whites reported better mean score on bodily pain compared to non-whites. This 
difference was significant at a p-value of 0.0327. No other variable of interest show 
any significant association with bodily pain. 
Table. 13: Multiple Chi-Square tests done on "Vitality/Fatigue" (Categorical) 
and other Independent Variables (Categorical) for people on anti-retroviral 
medication. 
The variable "gender" was found to be significantly associated with "vitality" (p-
value= 0.0047). Females had better score on vitality than their male counterparts. No 
other variable show any significant association with vitality. 
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Table. 14: Multiple Chi-Square tests done on "Mental Health" (Categorical) and 
other Independent Variables (Categorical) for people on anti-retroviral 
medication. 
No variable show any significant association with the variable "mental health". 
Table. 15: Multiple Chi-Square tests done on "General Health" (Categorical) and 
other Independent Variables (Categorical) for people on Protease Inhibitors 
medication. 
The variable "years of education" was found to be significantly associated with 
"general health". Patients with more than 12 years of education had better mean score 
of general health than patients with less than 12 years of education (p-value= 0.026). 
Table. 16: Multiple Chi-Square tests done on "Bodily Pain" (Categorical) and 
other Independent Variables (Categorical) for people on Protease Inhibitor 
medication. 
The variable "annual family income" was found to be significantly associated with 
"bodily pain". Patents with annual family income more than $15,000 reported better 
mean score on bodily pain compared to patients with annual income less than $15,000. 
No other variable of interest show any significant association with bodily pain. 
Table. 17: Multiple Chi-Square tests done on "Vitality/Fatigue" (Categorical) 
and other Independent Variables (Categorical) for people on Protease Inhibitor 
medication: 
No variable show any significant association with the variable "vitality/fatigue". 
Table. 18: Multiple Chi-Square tests done on "Mental Health" (Categorical) and 
other Independent Variables (Categorical) for people on Protease Inhibitor 
medication. 
The variable "gender" was found to be significantly associated with "mental health". 
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( Females reported better mental health compared to males (p-value= 0.032). No other 
variable of interest show any significant association with bodily pain. 
Table. 19: Logistic Regression Analysis between Adherence to Anti-retroviral 
Medication with a 95% cut-off (Dependent Variable) and Independent Variables 
of Primary Interest. 
This table summarizes the final logistic model run between dependent variable (95% 
adherence) and each of primary independent variable controlling for the confounding 
variables as described by Kleinbaum [ 44]. 
Table. 20: Logistic Regression Analysis between Adherence to Anti-retroviral 
Medication using MAS (Dependent Variable) and Independent Variables of 
Primary Interest. 
This table summarizes the final logistic model run between dependent variable (MAS 
adherence) and each of primary independent variable controlling for the confounding 
variables (as described by Kleinbaum). 
Table. 21: Logistic Regression Analysis between Adherence to Protease-
inhibitor Medication with a 95% cut-off (Dependent Variable) and Independent 
Variables of Primary Interest. 
This table summarizes the final logistic model run between dependent variable (95% 
adherence) and each of primary independent variable controlling for the confounding 
variables. The variable "gender" was found to be significantly associated with both 
95% adherence and mental health. 
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( Table. 22: Logistic Regression Analysis between Adherence to Protease-inhibitor Medication using MAS (Dependent Variable) and Independent 
Variables of Primary Interest. 
This table summarizes the final logistic model run between dependent variable (MAS 
adherence) and each of primary independent variable controlling for the confounding 
variables. The variable "annual family income" was found to be significantly 
associated with both MAS adherence and bodily pain. 
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Table 1: Demographics and Clinical Characteristics of Patient Population on 
Anti-retroviral Medication: 
Demographic N(%) 
Variables 
Age 
<35 years 39(29.77) Mean=39.38 Median=38 
35-41 years 45(34.35) Min=24 Max=57 
>41 years 47(35.88) S.D.= 7.51 
Years of Education Mean=l2.12 Median=l2 
<12 years 43(32.82) Min=O Max=22 
::::12 years 88(67.18) S.D.=2.85 
Gender 
Female 35(26.92) 
Male 95(73.08) 
Race 
Whites 84(64.12) 
Non-whites: 47(35.88) 
-Native American 
-Hispanic 
-Asian 
-African American 
-others 
Living arrangement 
Alone 38(29.01) 
With others 93(70.99) 
Annual Household 
Income 75(60.48) 
<15,000 49 (39.52) 
> 15,000 
Insurance 
Some 110(83.97) 
None 21(16.031 
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Clinical Variable N(%) 
Current Health Status 
Excellent-Good 100(72.99) 
Fair-Poor 37(27.01) 
Time Since Diawosis 
<1 month-2years 22(16.92) 
3-4 years 24(18.46) 
~ 5 _years 84(64.62) 
T-cell Count 
:S200 60(47.62) 
>200 66(52.38) 
IV Drug Use 
Never or not in past 126(96.18) 
6 months 
Occasionally 5_Q.82) 
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Table 2: Demographics and Clinical Characteristics of Patient Population on 
Protease-inhibitor Medication: 
Demographic N(%) 
Variables 
Age 
<35 years 18(24.32) Mean=39.37 Median=38 
35-41 years 27(36.49) Min=24 Max=57 
>41 years 29(39.19) S.D.= 7.44 
Years of Education Mean=l2.88 Median=12 
<12 years 17(22.97) Min=O Max=22 
2'._12 _years 57.Q7.03) S.D.=3.19 
Gender 
Female 19(25.68) 
Male 55(74.32) 
Race 
Whites 57(77.03) 
Non-whites: 17 (22.97) 
-Native American 
-Hispanic 
-Asian 
-African American 
-others 
Living arrangement 
Alone 20(27.03) 
With others 54(72.97) 
Annual Household Income 
<1 5,000 43(57.33) 
>1 5,000 32(42.67) 
Insurance 
Some 9(12.16) 
None 65(87.84) 
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Clinical Variable N(%) 
Current Health Status 
Excellent-Good 62(80.52) 
Fair-Poor 15(19.48) 
Time Since Diagnosis 
<lmonth-2years 13(17.57) 
3-4 years 14(18.92) 
> 5 _years 47(63.51) 
T-cell Count 
::::200 39(54.93) 
>200 32(45.07) 
IV Drug Use 
Never or not in past 72(97.40) 
6 months 
Occasionally 2(2.60) 
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Table 3: Self-reported Quality of life of patients on antiretroviral medication by 
medication adherence: 
Primary 95% Self-reported Medication Adherence 
Independent Adherence Scale 
Variable Non-adherent Adherent Non-adherent Adherent 
N(%) N(%) N(%) N(%) 
Low Gen Health 6(13.64) 38(86.36) 26(55.32) 21(44.68) 
Hig_h Gen Health 10(11.49) 77(88.51) 49(54.44) 41(45.56) 
Low Bodily Pain 7(11.86) 52(88.14) 33(53.23) 29(46.77) 
High Bodily Pain 9(12.50) 63(87.50) 42(56.00) 33(44.00) 
Low Vitality 10(16.67) 50(83.33) 22(56.41) 17(43.59) 
High Vitality_ 6(8.45) 65(91.55) 53(54.08) 45(45.92) 
Low Mental Health 5(13.64) 30(86.36) 31(63.27) 18(36.73) 
Hig_h Mental Health 11(12.49) 85(87.51) 44(50.00) 44(50.00) 
Table 4: Self-reported Quality of life of patients on protease inhibitors by 
medication adherence: 
Primary 95% Self-reported Medication Adherence 
Independent Adherence Scale 
Variable Non-adherent Adherent Non-adherent Adherent 
N(%) N(%) N(%) N (o/tl 
Low Gen Health 4(17.39) 19(82.61) 12(52.17) 11(47.83) 
High Gen Health 8(15.69) 43(84.31) 28(51.85) 26(48.151 
Low Bodily Pain 6(17.65) 28(82.35) 20(58.82) 14(41.18) 
Hig_h Bodily Pain 6(15.001 34(85.00) 20(46.51) 23(53.49) 
Low Vitality 7(35.00) 13(65.00) 13(65.00) 7(35.00) 
High Vitality 5(9.26) 49(90.74) 27 (47.37) 30(52.63) 
Low Mental Health 9(25.71) 26(74.29) 22(61.11) 14(38.89) 
Hig_h Mental Health 3(7.69) 36(92.31) 18(43.90) 23(56.10) 
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Table 5: Mean and Range values of Quality of life domains (Primary IV) in 
patient on anti-retroviral drugs compared with general US population. 
pf t a 1en son Anf t . 1 d 1-re rovira ru_g_s: 
QoL Scales Mean Std Deviation Range 
General Health 51.29 28.01 5-85 
Bodily Pain 38.83 13.64 0-64 
Vitality 31.91 13.27 0-55 
Mental Health 31.76 9.93 0-60 
G lUSP 1 f enera o_p_u a 10n: 
QoL Scales Mean Std Deviation Range 
General Health 71.95 20.34 5-100 
Bodily Pain 75.15 23.69 0-100 
Vitality 60.86 20.96 0-100 
Mental Health 74.74 18.05 0-100 
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Table 6: Mean and Range values of Quality of life domains (Primary IV) in 
patients on protease inhibitors compared with general US population. 
Patients on Protease Inhibitors: 
QoL Scales Mean Std Deviation Range 
General Health 50.81 27.46 5-85 
Bodily Pain 39.08 13.33 0-64 
Vitality 33.19 12.40 0-55 
Mental Health 32.79 9.91 0-60 
G IUSP If enera O.J!.U a aon: 
QoL Scales Mean Std Deviation Range 
General Health 71.95 20.34 5-100 
Bodily Pain 75 .15 23.69 0-100 
Vitality 60.86 20.96 0-100 
Mental Health 74.74 18.05 0-100 
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Table 7: Multiple Chi-Square Tests done on the Adherence to Antiretroviral 
Medications with 95% Cut off (Categorical Dependent Variable) and other 
Categorical Independent Variables. 
Categorical I.V. Non-Adherent Adherent Chi-square 
N_i%l N_i%l _p_-value 
Age 
<35 years 7(17.95) 32(82.05) 2.7392 
35-41 years 6(13.33) 39(86.67) 0.2543 
>41 years 3(6.38) 44(93.62) 
Years of Education 
<12 years 5(11.63) 38(88.37) 0.0204 
2: 12 _years 11(12.50) 77(87.50) 0.8862 
Gender 
Male 11(11.58) 84(88.42) 0.1736 
Female 5(14.29) 30(85.71) 0.6762 
Insurance 
None 1(4.76) 20(95.24) 1.2952 
Some 15(13.64)) 95(86.36) 0.2551 
Ethnicity 
Whites 15(17.76) 69(82.14) 6.9546 
Non-Whites 1(2.13) 46(97.87) 0.0084* 
Living Arrangement 
Alone 5(13.16) 33(86.84) 0.0442 
With Others 11(11.83) 82(88.17) 0.8329 
Annual Family Income 
<15,000 66(85.71) 9(14.29) 0.0017 
>15,000 43(88.42) 6(11.58) 0.9674 
Time Since Diagnosis 
<1 month-2 years 2(9.09) 20(90.91) 
3-4 years 6(25.00) 18(75.00) 4.3973 
> 5years 8(9.521 76(90.48) 0.1110 
T-Cell Count 
::::200 5(8.33) 55(91.67) 1.3931 
>200 10(15.15) 56(84.85) 0.2379 
IV Drug Use 
No 1(20.00) 4(80.00) 0.2939 
Yes 15(11.90) 111(88.10) 0.5877 
* If a. s_0.05, then p- value is significant 
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Table 8: Multiple Chi-Square Tests done on the Adherence to Antiretroviral 
Medications using MAS (Categorical Dependent Variable) and other Categorical 
Independent Variables. 
Categorical I.V. Non-Adherent Adherent Chi-square 
N_i_o/ol N_tO/tl_ _p_-value 
Age 
<35 years 22(52.38) 20(47.62) 1.9000 
35-41 years 23(48.94) 24(51.06) 0.3867 
>4l_years 30(62.50) 18(37.50) 
Years of Education 
<12 years 25(53.19) 22(46.81) 0.0697 
2:12 years 50(55.56) 40(44.54) 0.7918 
Gender 
Male 55(56.12) 43(43.18) 0.1349 
Female 20(52.63) 18(47.37) 0.7134 
Insurance 
None 12(55.55) 10(44.45) 0.0004 
Some 63(54.78)) 52(45.22) 0.9837 
Ethnicity 
Whites 45(51.72) 42(48.28) 0.8788 
Non-Whites 30(60.00) 20l._40.0Q2_ 0.3488 
Living Arrangement 
Alone 24(60.00) 16(40.00) 0.6298 
With Others 51(52.581 46(47.42) 0.4274 
Annual Family Income 
<15,000 27(54.00) 23(46.00) 0.0356 
2:15,000 44(55.70) 35(44.30) 0.8503 
Time Since Dia~[!PSis 
<l month-2 years 12(52.17) 11(47.83) 0.1047 
3-4 years 14(56.00) 11(44.00) 0.9490 
'.'.:: 5 years 48(55.81) 38(44.19) 
T-Cell Count 
:::: 200 42(60.87) 27(39.13) 1.7903 
>200 30_{_49.18) 31(50.82) 0.1809 
IV Drug Use 
No 5(100.00) 0(00.00) 4.2899 
Yes 70(53.03) 62(46.97) 0.0383* 
* If a :s_0.05, then p- value is significant 
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( Table 9: Multiple Chi-Square Tests done on the Adherence to Protease Inhibitor Medications with 95% cut off (categorical Dependent Variable) and other 
Categorical Independent Variables. 
Categorical l.V. Non-Adherent Adherent Chi-square 
N_(_%J N_(_%l _p_-value 
Age 
<35 years 5(27.78) 13(72.22) 2.4142 
35-41 years 3(11.11) 24(88.89) 0.2991 
>41 years 4(13.79) 25(86.21) 
Years of Education 
<12 years 4(23.53) 13 (76.47) 0.8688 
2: 12 _years 8(14.04) 49(85 .96) 0.3513 
Gender 
Male 6(10.91) 49(89.09) 4.4407 
Female 6(31.58) 13(68.42) 0.0351 * 
Insurance 
None 12(18.46) 53(81.54) 1.9831 
Some 0(0.00) 9(100.00) 0.1591 
Ethnicity 
Whites 1(5.88) 16(94.12) 1.7347 
Non-Whites 11(19.30) 46(81.701 0.1878 
Living Arrangement 
Alone 8(14.81) 46(85.19) 0.2888 
With Others 4(20.00) 16(80.00) 0.5910 
Annual Family Income 
<15,000 8(19.51) 33(81.49) 0.6434 
>15,000 4(12.50) 28(87.50) 0.4225 
Time Since Diagnosis 
<1 month-2 years 2(15 .38) 11(84.62) 0.0674 
3-4 years 2(14.29) 11(85.71) 0.9668 
2: 5 years 8(17.02) 39(82.98) 
T-Cell Count 
::: 200 6(15.38) 33(84.62) 0.1417 
>200 6(18.75) 26(81.25) 0.7066 
IV Drug Use 
No 1(50.00) 1(50.00) 1.7268 
Yes 11(15.28) 61_(84.72) 0.1888 
* If a .:s._0.05, then p- value is significant 
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( Table 10: Multiple Chi-Square Tests done on the Adherence to Protease Inhibitor Medications using MAS (categorical Dependent Variable) and other 
Categorical Independent Variables. 
Categorical I.V. Non-Adherent Adherent Chi-square 
NJ.%1 NJ.%1 _!!_-value 
Age 
<35 years 11(50.00) 11(50.00) 0.2168 
35-41 years 15(55.56) 12(44.45) 0.8973 
>41 years 14(50.00) 1~50.00) 
Years of Education 
<12 years 10(58.82) 7 (41.18) 0.4132 
>12 years 30(50.00) 30(50.00) 0.5204 
Gender 
Male 28(49.12) 29(50.88) 1.1279 
Female 12(63.16) 7(36.84) 0.2886 
Insurance 
None 5(50.00) 5(50.00) 0.0175 
Some 35(52.24) 32(47.76) 0.8948 
Ethnicity 
Whites 28(48.28) 30(51.72) 1.2698 
Non-Whites 12(63.16) 7(36.84) 0.2598 
Living Arrangement 
Alone 12(54.55) 10(45.45) 0.0832 
With Others 28(50.91 ) 27(49.09) 0.7729 
Annual Family Income 
<15,000 26(60.47) 17(39.53) 2.0595 
>15,000 14(43.75) 18(56.25) 0.0151 * 
Time Since Dia@osis 
<1 month-2 years 7(46.67) 8(53.33) 0.2981 
3-4 years 8(50.00) 8(50.00) 0.8615 
> 5 years 25(54.35) 21(45.65) 
T-Cell Count 
:s 200 16(42.11) 22(57.89) 4.4904 
>200 24(66.67) 12(33.33) 0.0341 * 
IV Drug Use 
No 1(50.00) 1(50.00) 0.0031 
Yes 39(52.00) 36(48.00) 0.9954 
* If a :s_0.05, then p- value is significant 
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Table. 11: Multiple Chi-Square tests done on "General Health" (Categorical) and 
other Independent Variables (Categorical} for people on anti-retroviral 
medication: 
Independent Poor Health Good Health Chi-square 
Variables NJ_%l N_(_%l _I>_-value 
Age 
<35 years 13(33.33) 26(66.67) 0.0068 
35-41 years 15(33.33) 30(66.67) 0.9966 
>41 _Y.ears 16(34.04) 31(65.96) 
Years of Education 
<12 years 19(44.19) 24 (55.81) 3.2233 
::'.:12_Y.ears 25(28.41) 63(71.59) 0.0726 
Gender 
Male 29(30.53) 66(69.47) 1.0370 
Female 14(40.00) 21(60.00) 0.3085 
Insurance 
None 10(47.62) 11(52.38) 2.2073 
Some 34(30.91) 76(69.09) 0.1374 
Ethnicity 
Whites 22(5.88) 62(94.12) 5.7434 
Non-Whites 22(19.30) 25(81.70) 0.0166 
Living Arrangement 
Alone 11(28.95) 27(71.05) 0.5167 
With Others 33_{_35.48) 60(64.52) 0.4722 
Annual Family Income 
<15,000 32(42.67) 43(57.33) 4.9097 
::'.:15,000 8(16.33) 41(83.67) 0.0022* 
IV Drug User 
No 3(60.00) 2(40.00) 1.6257 
Yes 41(32.54) 85(67.46) 0.2023 
Time Since Dia@osis 
0-2 years 6(27.27) 16(72.73) 0.5849 
3-4 years 9(37.50) 15(62.50) 0.7464 
::'.:5 _Y.ears 29_{_34.52) 55(65.48) 
T-Cell Count 
S200 21(31.82) 45(68.18) 0.0329 
>200 20(33.33) 40(66.67) 0.8561 
* If a :s_0.05, then p- value is significant 
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Table. 12: Multiple Chi-Square tests done on "Bodily Pain" (Categorical) and 
other Independent Variables (Categorical) for people on anti-retroviral 
medication: 
Independent Poor Health Good Health Chi-square 
Variables N_{O/tl N_{_%l _Q-value 
Age 
<35 years 14(35.90) 25(64.10) 2.0540 
35-41 years 21(46.67) 24(53.33) 0.3581 
>41 _years 24(51 .06) 23(48.94) 
Years of Education 
<12 years 22(51.16) 21 (48.84) 0.9700 
>12 _years 37(42.05) 51(57.95) 0.3247 
Gender 
Male 44(46.32) 51(53.68) 0.1234 
Female 15(42.86) 20(57.14) 0.7253 
Insurance 
None 11(52.38) 10(47.62) 0.5447 
Some 48(30.91) 62(69.09) 0.4605 
Ethnicity 
Whites 32(38.10) 52(61.90) 4.5593 
Non-Whites 27(57.45) 20(42.55) 0.0327* 
Living Arrangement 
Alone 19(50.00) 19(50.00) 0.5324 
With Others 42(43 .01) 53(56.99) 0.4656 
Annual Family Income 
<15,000 44(58.67) 31(41.33) 13.9781 
>15,000 12(24.49) 37(75.511 0.0002 
IV Drug User 
No 2(40.00) 3(60.00) 0.0533 
Yes 57(45.24) 69(54.76) 0.8174 
Time Since Diagnosis 
0-2 years 8(36.36) 14(63.64) 2.0461 
3-4 years 9(37.50) 15(62.50) 0.3595 
2:5 _years 42(50.00) 42(50.00) 
T-Cell Count 
:::: 200 29(48.33) 31(51.67) 0.4430 
>200 28(48.33) 38(57.67) 0.5057 
*If a :s_0.05, then p- value is significant 
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{ Table. 13: Multiple Chi-Square tests done on "Vitality/Fatigue" (Categorical) 
and other Independent Variables (Categorical) for people on anti-retroviral 
medication: 
Independent Poor Health Good Health Chi-square 
Variables NJ.%1 N(%l ]!_-value 
Age 
<35 years 19(48.72) 20(51.28) 0.8536 
35-41 years 22(48.89) 23(51.11) 0.6526 
>41 years 19(40.43) 28(59.57) 
Years of Education 
<12 years 22(51.16) 21 (48.84) 0.7412 
2:12 years 38(43.1 8) 50(56.82) 0.3893 
Gender 
Male 36(37.89) 59(62.11) 7.8997 
Female 23(65.71) 12(34.29) 0.0047* 
Insurance 
None 9(46.36) 12(53.67) 0.0873 
Some 51(42.86) 59(57.14) 0.7676 
Ethnicity 
Whites 39(46.43) 45(53.57) 0.0371 
Non-Whites 21(44.68) 26(55.321 0.8473 
Living Arrangement 
Alone 15(39.47) 23(60.53) 0.8634 
With Others 45(48.39) 48(51.61) 0.3528 
Annual Family Income 
<15,000 42(56.00) 33(44.00) 6.4888 
>15,000 16(32.65) 33(67.35) 0.0109* 
IV Drug User 
No 4(80.00) 1(20.00) 2.4492 
Yes 56(44.44) 70(55.56) 0.1176 
Time Since Diaggosis 
0-2 years 11(27.27) 11(72.73) 1.4043 
3-4 years 13(37.50) 11(62.50) 0.4995 
2:5 years 35(41.67) 49(58.33) 
T-Cell Count 
<200 26(39.39) 40(60.61) 1.9108 
>200 31(51.67) 29(48 .33) 0.1669 
*If a s_0.05, then p- value is significant 
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Table. 14: Multiple Chi-Square tests done on "Mental Health" (Categorical) and 
other Independent Variables (Categorical) for people on anti-retroviral 
medication: 
Independent Variables Poor Fair Health Good Chi-square 
Health Health p-value 
NJ.%1 N _(%~}_ NJ.%1 
Age 
<35 years 12(30.71) 22(56.41) 5(12.82) 4.1061 
35-41 years 12(26.67) 21(46.67) 12(26.67) 0.1283 
>41 _years 11(23.40) 20(42.55) 16(34.04}_ 
Years of Education 
<12 years 11(25.58) 21 (48.84) 11 (25.58) 0.0089 
>12 _years 24(27.27) 42(47.73) 22(25.00) 0.9248 
Gender 
Male 21(22.11) 48(50.53) 26(27.37) 2.7903 
Female 14(40.00) 14(40.00) 7(20.00) 0.0948 
Insurance 
None 7(33.33) 10(47.62) 4(19.05) 0.4162 
Some 28(25.45) 53(48.18) 29(26.36) 0.5188 
Ethnicity 
Whites 22(26.19) 41(48.81) 21(25.00) 0.0070 
Non-Whites 13(27.66) 22(46.81) 12_{_25.53) 0.9333 
Living Arrangement 
Alone 12(31.58) 18(47.37) 8(21.05) 1.5111 
With Others 23(24.73) 45(48.39) 25_{_26.88) 0.2191 
Annual Family Income 
<15,000 22(29.33) 33(44.00) 20(26.67) 0.8399 
>15,000 9_{_18.37) 28(57.14) 12(24.49) 0.3594 
IV Drug User 
No 0(00.00) 5(100.00) 0(00.00) 1.2218 
Yes 35(27.78) 58(46.03) 33(26.19) 0.2690 
Time Since Diawosis 
0-2 years 7(31.82) 9(40.91) 6(27.27) 0.4131 
3-4 years 6(25.00) 13(54.17) 5(20.83) 0.8134 
2:5 _years 21(25 .00) 41_{_48.81:2_ 22(26.19) 
T-Cell Count 
:::; 200 21(31.82) 31(46.97) 14(21.21) 1.5551 
>200 13(21.67) 31(51.67) 16(26.67) 0.2124 
* If a :s_0.05, then p- value is significant 
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Table. 15: Multiple Chi-Square tests done on "General Health" (Categorical) and 
other Independent Variables (Categorical) for people on Protease Inhibitors 
medication: 
Independent Poor Health Good Health Chi-square 
Variables NJ.%1 NJ.%1 _E_-value 
Age 
<35 years 8(44.44) 10(55.56) 2.0009 
35-41 years 7(25 .93) 20(74.07) 0.3667 
>41 years 8(27.59) 21(72.41) 
Years of Education 
<12 years 9(52.94) 8 (47.06) 4.9235 
2: 12 _years 14(24.56) 43(75.44) 0.0265* 
Gender 
Male 16(29.09) 39(70.91) 0.3961 
Female 7(36.84) 12(63.16) 0.5291 
Insurance 
None 3(33.33) 6(66.67) 0.0243 
Some 20(30.77) 45(69.23) 0.8762 
Ethnicity 
Whites 15(26.32) 42(73 .68) 2.6303 
Non-Whites 8(47.06) 9(52.94) 0.1048 
Living Arrangement 
Alone 5(25.00) 15(75.00) 0.4731 
With Others 18(33.33) 36(66.671 0.4915 
Annual Family Income 
<15,000 16(39.02) 25(60.98) 3.5088 
2:15,000 6(18.75) 26(81.251 0.0610 
IV Drug User 
No 1(50.00) 1(50.00) 0.3435 
Yes 22(30.56) 50(69.44) 0.5578 
Time Since Diaggosis 
0-2 years 5(38.46) 8(61.54) 0.7277 
3-4 years 5(35.71) 9(64.29) 0.6950 
2:5 _years 13(27.66) 34_{_72 .3~ 
T-Cell Count 
:s 200 10(31 .25) 22(68.75) 0.0782 
>200 11(28.21) 28(71.79) 0.7797 
* If a :s_0.05, then p- value is significant 
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Table. 16: Multiple Chi-Square tests done on "Bodily Pain" (Categorical) and 
other Independent Variables (Categorical) for people on Protease Inhibitor 
medication: 
Independent Poor Health Good Health Chi-square 
Variables NJ%l NJ%l 1!_-value 
Age 
<35 years 10(55.56) 8(44.44) 0.9784 
35-41 years 11(40.74) 16(59.26) 0.6131 
>41 years 13(44.83) 16(55.17) 
Years of Education 
<12 years 9(52.94) 18 (47.06) 0.4348 
::::12 _years 25(43.86) 32(56.14) 0.5096 
Gender 
Male 24(43.64) 31(56.36) 0.4601 
Female 10(52.63) 9(47.37) 0.4976 
Insurance 
None 4(44.44) 5(55.56) 0.0093 
Some 20(46.15) 35(53.85) 0.9232 
Ethnicity 
Whites 24(42.11) 33(57.89) 1.4737 
Non-Whites 10(58.82) 7(41.18) 0.2248 
Living Arrangement 
Alone 9(45.00) 11(55.00) 0.0099 
With Others 25(46.301 29(53.70) 0.9208 
Annual Family Income 
<15,000 25(60.98) 16(39.02) 7.7947 
2:15,000 9(28.13) 23(71.88) 0.0052* 
IV Drug User 
No 1(50.00) 1(50.00) 0.0136 
Yes 33(45.831 39(54.17) 0.9072 
Time Since Diagrrosis 
0-2 years 4(30.77) 9(69.23) 1.4675 
3-4 years 7(50.00) 7(50.00) 0.4801 
2:5 years 23(48.94) 24(51.06) 
T-Cell Count 
S200 15(46.88) 17(53.13) 0.0766 
>200 17(43.59) 22(56.41) 0.7819 
* If a :s_0.05, then p- value is significant 
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Table. 17: Multiple Chi-Square tests done on "Vitality/Fatigue" (Categorical) 
and other Independent Variables (Categorical) for people on Protease Inhibitor 
medication: 
Independent Poor Health Good Health Chi-square 
Variables N_{_%l N_{_%l __p_-value 
Age 
<35 years 8(44.44) 10(55.56) 3.6753 
35-41 years 6(22.22) 21(77.78) 0.1592 
>41 years 6(20.69) 23(79.31) 
Years of Education 
<12 years 6(35.29) 11 (64.71) 0.7648 
2:12 _years 14(24.56) 43(75.44) 0.3818 
Gender 
Male 12(21.82) 43(78.18) 2.9469 
Female 8(42.11) 11(57.89) 0.0860 
Insurance 
None 3(33.33) 6(66.67) 0.2066 
Some 17(26.15) 48(73.85) 0.6494 
Ethnicity 
Whites 15(26.32) 42(73 .68) 0.0636 
Non-Whites 5(29.41) 12(70.59) 0.8008 
Living Arrangement 
Alone 6(30.00) 14(70.00) 0.1228 
With Others 14(25.93) 40(74.07) 0.7260 
Annual Family Income 
<15,000 14(34.15) 27(65 .85) 2.1418 
2:15,000 6_(18.75) 26(81.25) 0.1433 
IV Drug User 
No 1(50.00) 1(50.00) 0.5509 
Yes 19(26.39) 53(73.61) 0.4583 
Time Since Diagnosis 
0-2 years 6(46.15) 7(53.85) 3.2163 
3-4 years 4(28.57) 10(71.43) 0.2003 
2:5 _years 10_{_21.281 37_{_78.72) 
T-Cell Count 
:s 200 7(21.88) 25(78.13) 0.1406 
>200 13(33.33) 26(66.67) 0.2855 
* If a :s__0.05, then p- value is significant 
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Table. 18: Multiple Chi-Square tests done on "Mental Health" (Categorical) and 
other Independent Variables (Categorical) for people on Protease Inhibitor 
medication: 
Independent Poor Health Good Health Chi-square 
Variables N(%) N(%) p-value 
Age 
<35 years 12(66.67) 6(33.33) 
35-41 years 11(40.74) 16(59.26) 3.5822 
>41 _years 12(41.38) 17(58.62) 0.1668 
Years of Education 
<12 years 9(52.94) 8 (47.06) 0.2820 
2:12 years 26(45.61) 31(54.39) 0.5954 
Gender 
Male 22(40.00) 33(60.00) 4.5761 
Female 13(68.421 6_(31.58) 0.0324* 
Insurance 
None 3(33.33) 6(33.67) 0.8013 
Some 32(49.23) 33(50.77) 0.3706 
Ethnicity 
Whites 29(50.88) 28(49.12) 1.2756 
Non-Whites 6(35.29) 11(64.71) 0.2587 
Living Arrangement 
Alone 11(55.00) 9(45.00) 0.6524 
With Others 24(44.44) 30(55.56) 0.4193 
Annual Family Income 
<15,000 21(51.22) 20(48.78) 04018 
>15,000 14(43.75) 18(56.25) 0.5262 
NDrugUser 
No 1(50.00) 1(50.00) 0.0060 
Yes 34(47.221 38(52.78) 0.9381 
Time Since Diagnosis 
0-2 years 7(53.85) 6(46.15) 1.0278 
3-4 years 5(35.71) 9(64.29) 0.5981 
>5 years 23(48.94) 24(51.06) 
T-Cell Count 
:::: 200 15(46.88) 17(53.13) 0.0239 
>200 19_(48.721 20(51.28) 0.8771 
*If a :s_0.05, then p- value is significant 
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Table. 19: Logistic Regression Analysis between Adherence to Anti-retroviral 
Medication with a 95% cut-off (Dependent Variable) and Independent Variables 
of Primary Interest 
Independent Variables Odds ratio Para Wald 
Point 95% C.I. estimate p-
estimate value 
General Health (high= 1, low=O) 0.778 0.19-3.10 -0.251 0.7219 
Gender (M=l, F=O) 0.753 0.21-3.60 -0.284 0.6540 
Education (2:12yrs=l, <12yrs=O) 1.056 0.28-3 .86 -0.054 0.9344 
Family Income 0.792 0.212-2.87 -0.233 0.7225 
(<15,000=1, >15,000=0) 
Ref-Low diag time (<2 yrs) 
Med diag time (3-4yrs=l, else=O) 0.330 0.05-1.98 0.109 0.2258 
High diag time (2:5 yrs=l, else=O) 1.425 0.25-7.84 0.354 0.6840 
T-cell Count (:S200= 1, >200=0) 1.458 0.42-4.99 0.376 0.5487 
Bodily Pain (high=l, low=O) 0.972 0.28-3.31 -0.027 0.9644 
Ref-Low age (<35yrs) 
Med age (35-41yrs=l, else=O) 1.153 0.32-4.04 0.142 0.8241 
H!_g_h a_g_e (>41_1'.!:_s=l, else=O) 3.401 0.61-18.78 0.223 0.1600 
Family Income 1.103 0.29-3.61 0.036 0.9543 
(<15,000=1, 2:15,000=0) 
T-cell Count (:S200= 1, >200=0) 1.387 0.41-4.66 0.327 0.5966 
Vital~Fat!.g_ue (hi_g_h= 1, low=O) 2.421 0.66-8.81 0.884 0.1799 
Gender (M=l, F=O) 0.940 0.26-3.38 -0.061 0.9249 
Family Income 1.041 0.30-3.61 0.041 0.9479 
(<15,000=1, 2:15,000=0) 
Ref-Low diag time ( <2 yrs) 
Med diag time (3-4yrs=l, else=O) 0.323 0.05-1.94 -1.131 0.2168 
High di'!S_ time (2:5 yrs= 1, else=O) 1.311 0.23-7.36 0.270 0.7584 
T-cell Count (:S200= 1, >200=0) 1.630 0.46-5.68 0.488 0.4424 
Mental Health 
Ref-HighMH 
Low MH = 1, else=O 0.289 0.29-2.83 -1.241 0.2863 
Med MH = 1, else=O 0.228 0.27-1.94 -1.478 0.1766 
Ref-Low age (<35yrs) 
Med age (35-41yrs=l, else=O) 1.045 0.29-3.66 0.043 0.9457 
Hig_h ~e (>4b'!:_s=l, else=O) 2.837 051-15.58 1.048 0.2307 
Family Income 0.973 0.29-3.21 -0.012 0.9838 
(<15,000=1, 2:15,000=0) 
T-cell Count (:S200= 1, >200=0) 1.490 0.43-5.01 0.398 0.5257 
* If a s_0.05, then p- value is significant 
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( Table. 20: Logistic Regression Analysis between Adherence to Protease Inhibitors with a 95% cut-off (Dependent Variable) and Independent Variables 
of Primary Interest 
Independent Variables Odds ratio Para Wald 
Point 95% C.I. estimate p-
estimate value 
General Health (hig_h= 1, low=O) 1.788 0.36-8.75 0.581 0.4735 
Gender (M=l, F=O) 0.214 0.04-0.96 -1.539 0.0451 
Race (whites=l, others=O) 0.200 .02-1.94 -1.608 0.1659 
Living Status (alone=l, other=O) 0.412 0.08-2.11 -0.886 0.2855 
Family Income 0.870 0.18-4.16 -0.136 0.8658 
(<15,000=1, >15,000=0) 
T-cell Count (::::200=1, >200=0) 1.252 0.30-5.19 0.225 0.5764 
Bodi~ Pain (hi_g_h= 1, low=O) 0.999 0.26-3.73 -0.001 0.9986 
Living Status (alone=l, other=O) 0.709 0.17-2.96 -0.343 0.6378 
Family Income 0521 0.12-2.17 -0.652 0.3709 
_{_<15,000=1, ~15,000=0) 
T-cell Count ( S200=1, >200=0) 1.543 0.39-5.98 0.433 0.5307 
Vitality/ Fat!g_ue _{_hi_g_h=l, low=Ol 4.482 1.10-18.13 1.500 0.0354 
Gender (M=l, F=O) 0.310 0.07-1.30 -1.171 0.1108 
Race (whites=l, others=O) 0.185 0.19-1.83 -1.688 0.1469 
Education (~12_2'.!:_s=l, <12_2'.!:_s=O) 1.954 0.42-9.02 0.670 0.3901 
Family Income 0.921 0.21-4.01 -0.082 0.9126 
(<15,000=1, ~15,000=0l 
Mental Health (hi_g_h= 1, low=O) 3.382 0.79-14.38 1.218 0.0990 
Gender (M=l, F=O) 0.327 0.08-1.26 -1.119 0.1045 
T-cell Count (S200=1, >200=0) 1.175 0.31-4.42 0.161 0.8117 
* If a< 0.05, then p- value is significant 
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( Table. 21: Logistic Regression Analysis between Adherence to Anti-retroviral drugs using MAS Scale and Independent Variables of Primary Interest 
Independent Variables Odds ratio Para Wald 
Point 95% estimate p-
estimate C.I. value 
General Health (hig_h=l, low=O)) 0.948 0.41-2.18 -0.053 0.9008 
Race (whites=!, others=O) 1.246 0.56-2.76 0.219 0.5889 
Family Income 0.827 0.38-1.78 -0.189 0.6298 
(<15,000=1, >15,000=0) 
T-cell Count (_:s200=1, >200=0) 1.743 0.83-3.64 0.555 0.1392 
Bodily Pain i_hi_g_h=l, low=O) 0.623 0.28-1.36 -0.472 0.2371 
Family Income 0.687 0.30-1.53 -0.375 0.3593 
(<15,000=1, ::::15,000=0) 
T-cell Count (S200= 1, >200=0) 1.726 0.82-3.80 0.545 0.1458 
Vital~ Fat!_g_ue (high=l, low=O) 1.136 0.52-4.47 0.127 0.7473 
T-cell Count (_:s200= 1, >200=0) 1.625 0.80-3.27 0.485 0.1744 
Mental Health (high=l, low=O) 1.836 0.81-4.13 0.607 0.1421 
Ref-Low age (<35yrs) 
Med age (35-41yrs=l, else=O) 1.019 0.40-2.54 0.019 0.9672 
H!&h a_g_e (>41_2'!'5= 1, else=O) 0.542 0.20-1.44 -0.613 0.2209 
Livin_g_ Status (alone= I, other=O) 0.744 0.32-1.72 -0.295 0.4913 
Family Income 0.841 0.39-1.80 -0.173 0.6567 
(<15,000=1, ::::I5,000=Q2_ 
T-cell Count (_:s200=1, >200=0) 1.891 0.87-4.01 0.636 0.1075 
* If a :s_0.05 , then p- value is significant 
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Table. 22: Logistic Regression Analysis between Adherence to Protease 
Inhibitors using MAS Scale and Independent Variables of Primary Interest 
Independent Variables Odds ratio Para Wald 
Point 95% estimate p-
estimate C.I. value 
General Health (hi_g_h= 1, low=O) 0.962 0.29-3.19 -0.038 0.9499 
Ref-Low age (<35yrs) 
Med age (35-4lyrs=l, else=O) 1.013 0.28-3.58 0.013 0.9839 
High age (>4lyrs=l, else=O) 0.739 0.20-2.67 -0.302 0.6453 
Race (whites=l, others=O) 2.719 0.74-9.93 1.000 0.1305 
T-cell Count (S200= 1, >200=0) 3.500 1.26-9.71 1.252 0.0161 
Bodi~ Pain (hi_g_h= 1, low=Ol 1.241 0.42-3.59 0.2163 0.6900 
Gender (M=l, F=O) 0.797 0.23-3.72 -0.2263 0.7184 
Race (whites=l, others=O) 2.241 0.62-7.71 0.8070 0.2004 
-Family Income 0.399 0.13-1.20 -0.9184 0.1021 
(<15,000=1, 2:15,000=0) 
T-cell Count (S200= 1, >200=0) 3.381 1.14-10.03 1.2183 0.0281 
Vitali_9'!Fat~ue (hi_g_h= 1, low=O) 2.468 0.67-9.02 0.903 0.1720 
Ref-Low age (<35yrs) 
Med age (35-41yrs=l, else=O) 0.591 0.15-2.29 -0.526 0.4466 
High ag_e (>4lY!"_s=1, else=O) 0.374 0.08-1.16 -0.984 0.1868 
Race (whites=l, others=O) 2.248 0.60-8.35 0.810 0.2238 
Family Income 0.311 0.10-0.96 -1.168 0.0423 
(<15,000=1, >15,000=0) 
T-cell Count (S200=1, >200=0) 4.884 1.47-16.18 1.586 0.0095 
Mental Health (high=l, low=O) 2.849 0.92-8.73 1.046 0.0690 
Ref-Low age (<35yrs) 
Med age (35-41yrs=l, else=O) 0.542 0.27-1.22 -0.613 0.3872 
High ~e _i>4b'.!:_s=1, else=Ol 0.336 0.14-1.02 -1.090 0.1520 
Race (whites=l, others=O) 2.393 0.64-9.12 0.872 0.2032 
Education (2:12-1'.!:_s=l, <12__TI_s=O) 1.823 0.49-6.70 0.600 0.3663 
Family Income 0.274 0.08-0.87 -1.295 0.0290 
_(_<15,000=1, 2:15,000=0) 
T-cell Count (S200=1, >200=0) 4.931 1.50-16.44 1.595 0.0094 
* If a s_0.05, then p- value is significant 
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DISCUSSION 
Adherence is an important factor to achieve the best outcomes in HN disease 
management [14]. Strict adherence to medication regimen in HN therapy is important 
for maintaining low viral loads. The purpose of this study was to assess HRQoL as a 
predictor of medication adherence. Medication adherence scale and percentage 
adherence were used as measures of adherence in this study. A rather strict 95% cut-
off mark was selected to define adherence based on recent studies and literature 
review [17, 45]. Given the complexities of HN therapy and viral response, the 
alternative to strict adherence for many patients could be death. 
Various factors affect patient's ability and desire to adhere to medication regimens. 
Two demographic factors, namely "gender" and "annual family income", were found 
to be associated with 95% adherence and MAS adherence respectively in patients 
taking protease inhibitors. Males reported more adherence compared to females. This 
could be because HN positive females might feel more depressed, anxious, and 
distressed than HIV positive males [ 46]. Similarly, patients with high family income 
reported more adherence compared to patients with low family income. This 
association is difficult to interpret, as the cost per prescription is not known. Although 
wealthy patients have more financial access to medications then low-income patients, 
this advantage is offset by prescription coverage available to poor patients through 
Medicaid. No other meaningful association was found between any other 
demographic variable (age, years of education, living status, ethnicity, duration of 
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( illness, etc) and medication adherence in anti-retroviral or protease inhibitor drugs. 
This is consistent with previous studies and research [39, 47]. Any inconsistency could 
be explained by study limitations discussed later. 
In recent years, interest has increased in the measurement of HRQoL, in relation to 
health-care. In a chronic disease like HN, the patients' physical and mental health is 
significantly affected. The opportunistic infections experienced by AIDS patients 
often have detrimental effect on their physical and mental health. Fatigue, emotional 
and psychological stress is often associated with HN infection. In this study, many 
demographic and clinical factors were found to be associated with HRQoL domains. 
For patients on anti-retroviral medications: Physical health domains like "general 
health" and "bodily pain" were significantly associated with "ethnicity". Whites 
reported better "general health" and lower "bodily pain" than non-whites. Patients 
with high annual family income reported better general health and vitality that patients 
with annual family income of less than $15,000. This is consistent with Center for 
Disease Control findings [48]. Also, males reported better vitality and low fatigue than 
females. Previous research also confirms similar difference in perceived quality of life 
between males and females [33, 49]. 
For patients on protease inhibitors: "Years of education" and "annual family 
income" were significantly associated with both "general health" and "bodily pain". 
Patients with higher level of education and annual family income of more than 
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( $15,000 reported better general health and low bodily pain than their counterparts. 
This could be because educated people are less likely to adopt risk-taking behavior 
such as smoking, drugs, and unprotected sex [ 48]. Also, education and family income 
increases self-esteem and confidence, life opportunities and social support. It allows 
people to adopt healthier lifestyle and seek better treatment. As with patients on anti-
retroviral medications, gender was found to be significantly associated with "mental 
health" in patients on protease inhibitors. 
The patients in this study scored significantly lower on all domains of HRQoL than 
general US population (Results: Table 5 & 6). This suggests low HRQoL of HN 
patients. The results of this study indicate that "vitality/fatigue" is a significant 
predictor of medication adherence in patients taking protease inhibitors. However, no 
other domain of HRQoL showed any meaningful association with medication 
adherence. Patients with high vitality score were found to be more adherent and 
patients with low vitality score were found to be less adherent to their medication. 
This is consistent with the results of previous studies, which suggest association of 
poor mental health, particularly depression, with medication adherence [39]. 
Although, other domains of quality of life, especially physical health, were expected to 
be associated with medication adherence, the result of the study does not confirm the 
same. The limitations of the study could have affected results significantly. 
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( Limitations: 
Measurement of adherence: There is no way to measure adherence in the outpatient 
setting with absolute precision and accuracy [50]. Although no measure of adherence 
is perfect, self-reporting method, often, tends to overestimate medication adherence. 
Recall bias and patients subjectivity often influence patients responses to questions. 
This could lead to inaccurate statistical analysis and inaccurate results. 
Sample: A sample population of 145, although fairly large, could have led to 
sampling errors. Sex, IV drug users and race distribution was not typical of HIV 
population. The center for Disease control and prevention (CDC) reported that 18% 
were women; in this sample 27% of patients were women. The CDC reported 35% as 
intravenous drug users; in this sample only 4.3% reported IV drug use. The CDC 
reported 41 % White, 38% Black, 19% Latinos and 1 % Asians. Many variables were 
found to be skewed. Statistical techniques were used to rectify this shortcoming. 
The data was collected in 96-97, when combination therapies were recently 
introduced. This study precedes many currently available anti-retroviral drugs and 
HAART. Thus, the results of this study may not be generalizable to today. 
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CONCLUSION 
Though overestimation of self-reported medication adherence cannot be ruled out, 
patients in this study group reported good level of adherence. Approximately 85% of 
the patients were adherent based on 95% cut-off limit. This high level of adherence is 
necessary for the successful management of HIV. In-contrast, MAS showed that only 
55% of the patients were adherent to their medication. One of the mental health 
domains i.e. vitality/fatigue was found to be significantly associated with 95% self 
reported adherence in patients taking protease inhibitors. This study confirms that 
patients with good mental health are more likely to adhere to their medication 
regimen, using 95% cut-off adherence in patients taking protease inhibitors. 
All HIV patients scored considerably low on all health domains when compared with 
US general population. Interestingly, HIV patients scored lower on all domains when 
compared with medical conditions like diabetes, hypertension, arthritis, CHF, and 
clinical depression [33]. These scores suggest that HIV patients suffer from strong 
physical and mental impairments, and have low quality of life. Stable demographic 
factors, like sex, race, years of education, and annual income were found to predict 
HRQoL. These factors precede medication adherence. The society as well as public 
health professionals should take a note of this, designing new policies and 
interventions to improve patient's HRQoL. 
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( Many clinicians and clinical investigators now recogmse the importance of 
incorporating HRQoL into their routine clinical practice and into clinical studies. One 
of the aims of treating patients is to make them feel better and to function better in 
their day-to-day activities. This would positively change their beliefs and perceptions 
about disease and importance of treatment. The findings of this study could help us in 
designing interventions to enhance adherence. Improving quality of life, particularly 
controlling depression and improving vitality, appears to be the key for better 
medication adherence. 
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APPENDIX 
/*SAS PROGRAM TO MEASURE ADHERENCE USING 95% CUT-OFF 
LIMTI FOR PATIENTS ON ANTI-RETROVIRAL DRUGS*/ 
options nocenter linesize=72; 
libname rak:esh 'c:\Windows\Desktop\rakesh'; 
data rakesh 1; 
set rakesh.hivsurv; 
if qiilx= 'bactrim' then qiilx2a=O; 
if qii 1 x= 'acyclovir' then qii 1 x2a=O; 
if qiilx= 'pentamidine' then qiilx2a=O; 
if qiilx= 'zoloft' then qiilx2a=O; 
if qiilx= 'crixivan' then qiilx2a=O; 
if qiilx= 'ritonavir' then qiilx2a=O; 
if qiilx= 'saquinavir' then qiilx2a=O; 
if qiilx2a=O then qiilxl4=.; 
if qii lxl4=99 then qiilx2a=.; 
if qii lx2a=l then qii lx2a=24; 
if qii lx2a=2 then qii lx2a=36; 
if qiilx2a=3 then qiilx2a=45; 
if qiilx2a=4 then qiilx2a=90; 
if qiilx2a=5 then qiilx2a=180; 
if qiilx2a=6 then qiilx2a=270; 
if qii 1 x2a=7 then qii 1 x2a=360; 
if qiilx2a=8 then qiilx2a=450; 
medl= qiilxl4/qiilx2a; 
compl=l-medl; 
percomp 1=comp1*100; 
if qii2x= 'dapsone' then qii2x2a=O; 
if qii2x= 'leucovorin' then qii2x2a=O; 
if qii2x= 'ms contin' then qii2x2a=O; 
if qii2x= 'bactrim' then qii2x2a=O; 
if qii2x= 'theodur' then qii2x2a=O; 
if qii2x= 'crixivan' then qii2x2a=O; 
if qii2x= 'saquinavir' then qii2x2a=O; 
if qii2x= 'indinavir' then qii2x2a=O; 
if qii2x= 'litonavir' then qii2x2a=O; 
if qii2x2a=O then qii2xl4=.; 
if qii2xl4=99 then qii2x2a=.; 
if qii2x2a=l then qii2x2a=24; 
if qii2x2a=2 then qii2x2a=36; 
if qii2x2a=3 then qii2x2a=45; 
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( if qii2x2a=4 then qii2x2a=90; if qii2x2a=S then qii2x2a=180; 
if qii2x2a=6 then qii2x2a=270; 
if qii2x2a=7 then qii2x2a=360; 
if qii2x2a=8 then qii2x2a=450; 
med2= qii2x 14/qii2x2a; 
comp2=1-med2; 
percomp2=comp2 *100; 
if qii3x= 'acyclovir' then qii3x2a=O; 
if qii3x= 'bactrim' then qii3x2a=O; 
if qii3x= 'biaxin' then qii3x2a=O; 
if qii3x= 'clotrimazole' then qii3x2a=O; 
if qii3x= 'compazine' then qii3x2a=O; 
if qii3x= 'dapsone' then qii3x2a=O; 
if qii3x= 'diltiazem' then qii3x2a=O; 
if qii3x= 'fluconazole' then qii3x2a=O; 
if qii3x= 'mellaril' then qii3x2a=O; 
if qii3x= 'minocycline' then qii3x2a=O; 
if qii3x= 'motrin' then qii3x2a=O; 
if qii3x= 'oxandrin' then qii3x2a=O; 
if qii3x= 'vasotec' then qii3x2a=O; 
if qii3x= 'zantac' then qii3x2a=O; 
if qii3x= 'zovirax' then qii3x2a=O; 
if qii3x= 'crixivan' then qii3x2a=O; 
if qii3x= 'indinavir' then qii3x2a=O; 
if qii3x= 'invirase' then qii3x2a=O; 
if qii3x= 'norvir' then qii3x2a=O; 
if qii3x= 'ritonavir' then qii3x2a=O; 
if qii3x= 'saquinavir' then qii3x2a=O; 
if qii3x2a=O then qii3x14=.; 
if qii3x14=99 then qii3x2a=.; 
if qii3x2a=1 then qii3x2a=24; 
if qii3x2a=2 then qii3x2a=36; 
if qii3x2a=3 then qii3x2a=45; 
if qii3x2a=4 then qii3x2a=90; 
if qii3x2a=5 then qii3x2a=180; 
if qii3x2a=6 then qii3x2a=270; 
if qii3x2a=7 then qii3x2a=360; 
if qii3x2a=8 then qii3x2a=450; 
med3= qii3x14/qii3x2a; 
comp3=1-med3; 
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( percomp3=comp3*100; if percomp 1 =. then percomp 1 =O; 
if percomp2=. then percomp2=0; 
if percomp3=. then percomp3=0; 
totcomp= percomp 1 +percomp2+percomp3; 
ifpercompl=O and percomp2 NE 0 and percomp3 NE 0 then totcomp= totcomp/2; 
if percomp 1 NE 0 and percomp2= 0 and percomp3 NE 0 then totcomp= totcomp/2; 
if percomp 1 NE 0 and percomp2 NE 0 and percomp3= 0 then totcomp=totcomp/2; 
ifpercompl NE 0 and percomp2 NE 0 and percomp3 NE 0 then totcomp=totcomp/3; 
if percomp 1 NE 0 and percomp2=0 and percomp3= 0 then totcomp= totcomp; 
if percomp 1 =0 and percomp2 NE 0 and percomp3= 0 then totcomp= totcomp; 
if percomp 1 =O and percomp2=0 and percomp3 NE 0 then totcomp= totcomp; 
if totcomp=O then delete; 
compb=totcomp GE 95; 
noncompb=totcomp LT 95; 
/*PROGRAM TO CATEGORIZE INDEPENDENT VARIABLES*/ 
if qi4=l then qi4=l; 
else if qi4=2 or qi4=3 or qi4=4 or qi4=5 or qi4=6 then qi4=0; 
if qi5=0 then qi5=.; 
if qi29= 1 or qi29=2 or qi29=3 or qi29=4 then qi29= 1; 
if qi29=5 then qi29=2; 
if qi29=6 then qi29=3; 
if qi29=0 then qi29=.; 
if qi31 =O then qi31 =.; 
else if qi31 = 1 or qi31 =2 then qi31 =0; 
else if qi31= 3 or qi31=4 then qi31=1; 
if qvi52= 0 or qvi52=1 then qvi52=1; 
else if qvi52= 2 or qvi52=3 then qvi52=0; 
if qil GE 24 and qil Lt 35 then qil=l; 
else if qil GE 35 and qil LE 41 then qil =2; 
elseifqil GT41 thenqi1=3; 
ifqi5 LT 12 then qi5=0; 
else if qi5 GE 12 then qi5=1; 
ifqi19=0 then qi19=.; 
if qi 19=1 then qi 19=1; 
if qi19=2 then qi19=0; 
if qil9=3 then qi19=0; 
if qi 19=4 then qi 19=0; 
if qi19=5 then qi19=0; 
if qi18a=l then qi18a=O; 
if qi18a=2 then qi18a=1; 
if qi7=1 then qi7=1; 
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else if qi7=2 then qi7=0; 
sex=.; 
if qi2='f then sex=O; 
if qi2='m' then sex=l; 
if qi2=0 then sex=.; 
Mqil=.; 
ifqi1=2 thenMqil=l; 
els·e if qi 1 =1 or qi 1 =3 then Mqi 1 =0; 
Hqil=.; 
ifqi1=3 thenHqil=l; 
else if qi1=2 or qil=l then Hqil=O; 
Mqi29=.; 
if qi29=2 then Mqi29=1; 
else if qi29=1 or qi29=3 then Mqi29=0; 
Hqi29=.; 
if qi29=3 then Hqi29=1; 
else if qi29=1 or qi29=2 then Hqi29=0; 
/*PROGRAM TO MEASURE HRQoL *I 
if qi3=1 then qi3=5.0; 
if qi3=2 then qi3=4.4; 
if qi3=3 then qi3=3.4; 
if qi3=4 then qi3=2.0; 
if qi3=5 then qi3=1.0; 
if qi24=1 then qi24=6.0; 
if qi24=2 then qi24=5.4; 
if qi24=3 then qi24=4.2; 
if qi24=4 then qi24=3.1; 
if qi24=5 then qi24=2.2; 
if qi24=6 then qi24=1.0; 
if qi25=0 then qi25=.; 
if qi25=1 and qi24=99 then qi25=6.0; 
if qi25=2 and qi24=99 then qi25=4.75; 
if qi25=3 and qi24=99 then qi25=3.5; 
if qi25=4 and qi24=99 then qi25=2.25; 
if qi25=5 and qi24=99 then qi25=1.0; 
if qi25=1 and qi24=1 then qi25=6.0; 
if qi25=1 and qi24 GE 2 and qi24 LE 6 then qi25=5; 
if qi25=2 and qi24 GE 1 and qi24 LE 6 then qi25=4; 
if qi25=3 and qi24 GE 1 and qi24 LE 6 then qi25=3; 
if qi25=4 and qi24 GE l and qi24 LE 6 then qi25=2; 
if qi25=5 and qi24 GE l and qi24 LE 6 then qi25=1; 
if qi26=0 then qi26=6; 
if qi26=1 then qi26=5; 
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if qi26=2 then qi26=4; 
if qi26 GE 3 and qi26 LE 5 then qi26=3; 
if qi26 GE 6 and qi26 LE 7 then qi26=2; 
if qi26 GE 7 and qi26 LE 28 then qi26=1; 
if qi26=99 then qi26=.; 
if qi28a=O then qi28a=99; 
if qi28b=O then qi28b=99; 
if qi28c=O then qi28c=99; 
if qi28d=O then qi28d=99; 
if qi28e=O then qi28e=99; 
if qi28f=O then qi28f=99; 
if qi28g=O then qi28g=99; 
if qi28h=O then qi28h=99; 
if qi28i=O then qi28i=99; 
if qi28g=l then qi28g=6; 
if qi28g=2 then qi28g=5; 
if qi28g=3 then qi28g=4; 
if qi28g=4 then qi28g=3; 
if qi28g=5 then qi28g=2; 
if qi28g=6 then qi28g=l; 
if qi28i=l then qi28i=6; 
if qi28i=2 then qi28i=5; 
if qi28i=3 then qi28i=4; 
if qi28i=4 then qi28i=3; 
if qi28i=S then qi28i=2; 
if qi28i=6 then qi28i=l; 
if qi28b=l then qi28b=6; 
if qi28b=2 then qi28b=5; 
if qi28b=3 then qi28b=4; 
if qi28b=4 then qi28b=3; 
if qi28b=5 then qi28b=2; 
if qi28b=6 then qi28b=l; 
if qi28c=l then qi28c=6; 
if qi28c=2 then qi28c=5; 
if qi28c=3 then qi28c=4; 
if qi28c=4 then qi28c=3; 
if qi28c=5 then qi28c=2; 
if qi28c=6 then qi28c=l; 
if qi28f=l then qi28f=6; 
if qi28f=2 then qi28f=5; 
if qi28f=3 then qi28f=4; 
if qi28f=4 then qi28f=3; 
if qi28f=5 then qi28f=2; 
if qi28f=6 then qi28f=l; 
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; 
I 
GHr=qi3; 
BPr=qi24+qi25; 
RPr=qi26; 
Vrl =qi28a+qi28e+qi28g+qi28i; 
ifVrl GE 117 then Vrl=O; 
MHrl =qi28b+qi28c+qi28d+qi28f+qi28h; 
ifMHrl GE 123 then MHrl=O; 
data rakesh2; 
set rakesh 1; 
if qi28a=99 then qi28a=(qi28e+qi28g+qi28i)/3; 
if qi28b=99 then qi28b=(qi28c+qi28d+qi28f+qi28h)/4; 
if qi28c=99 then qi28c=(qi28b+qi28d+qi28f+qi28h)/4;; 
if qi28d=99 then qi28d=(qi28b+qi28c+qi28f+qi28h)/4; 
if qi28e=99 then qi28e=(qi28a+qi28g+qi28i)/3; 
if qi28f=99 then qi28f=(qi28b+qi28c+qi28d+qi28h)/4; 
if qi28g=99 then qi28g=(qi28a+qi28e+qi28i/3); 
if qi28h=99 then qi28h=(qi28b+qi28c+qi28d+qi28f)/4; 
if qi28i=99 then qi28i=(qi28a+qi28e+qi28g/3); 
V r=qi2 8a+qi28e+qi28 g+qi28i; 
ifVrl=O then Vr=.; 
MHr=qi28b+qi28c+qi28d+qi28f+qi28h; 
ifMHrl=O then MHr=.; 
GH=(GHr-1)/4*100; 
BP=(BPr-2)/1O*100; 
RP=(RPr-1)/5*100; 
V=(Vr-4)/20*100; 
MH=(MHr-5)/25*100; 
ifGH LT 60 then GH=O; 
else ifGH GE 60 then GH=l; 
if BP LT 42 then BP=O; 
else if BP GE 42 then BP=l; 
ifV LT 35 then V=O; 
else ifV GE 35 then V=l; 
ifMH LT 28 then MH=O; 
ifMH GE 28 and MH LT 40 then MH=l; 
else if MH GE 40 then MH=2; 
LMH=.; 
ifMH=O then LMH=l; 
else ifMH=l or MH=2 then LMH=O; 
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MMH=.; 
ifMH=l then MMH=l; 
else if MH=O or MH=2 then MMH=O; 
keep Mqil Hqil sex qi4 qi5 qi7 qi18a qi19 Mqi29 Hqi29 qi31 qvi52 GH BP V LMH 
MMH compa compb; 
/*proc freq; 
proc univariate normal plot; 
proc freq; 
tables MH*qi l/all; 
tables MH*sex/all; 
tables MH*qi4/all; 
tables MH*qi5/a11; 
tables MH*qi7/all; 
tables MH*qi l 8a/all; 
tables MH*qi 19/all; 
tables MH*qi29/all; 
tables MH*qi3 l/all;*/ 
proc logistic descending; 
model compb = LMH MMH Mqi 1 Hqi 1 qi 19 qi31/ctable pprob=(O to 1 by .1 ) lackfi t 
risklimits; 
run; 
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( /*SAS PROGRAM TO MEASURE ADHERENCE USING 95% CUT-OFF LIMIT FOR PATIENTS TAKING PROTEASE INHIBITORS*/ 
options nocenter linesize=72; 
libname rakesh 'c:\ Windows\Desktop\rakesh'; 
data rakeshl; 
set rakesh.hivsurv; 
if qiilx= 'acyclovir' then qiilx2a=O; 
if qiilx= 'pentarnidine' then qiilx2a=O; 
if qiilx= 'bactrim' then qiilx2a=O; 
if qiilx= 'zoloft' then qiilx2a=O; 
if qii lx= '3tc' then qiilx2a=O; 
ifqiilx= 'azt' then qiilx2a=O; 
if qiilx= 'd4t' then qiilx2a=O; 
if qii 1 x= 'ddc' then qii 1 x2a=O; 
if qiilx= 'ddi' then qiilx2a=O; 
if qiilx= 'zerit' then qiilx2a=O; 
if qiilx= 'epivir' then qiilxla=O; 
if qiilx2a=O then qii lx14=.; 
if qiilx14=99 then qiilx2a=.; 
if qiilx2a=l then qiilx2a=24; 
if qii lx2a=2 then qii lx2a=36; 
if qii lx2a=3 then qii 1 x2a=45; 
if qii 1 x2a=4 then qii 1 x2a=90; 
if qiilx2a=5 then qiilx2a=l80; 
ifqiilx2a=6 then qiilx2a=270; 
if qiilx2a=7 then qii lx2a=360; 
if qiilx2a=8 then qiilx2a=450; 
medl= qiilx14/qiilx2a; 
compl=l-medl; 
percompl=compl *100; 
if qii2x= 'bactrim' then qii2x2a=O; 
if qii2x= 'dapsone' then qii2x2a=O; 
if qii2x= 'leucovorin' then qii2x2a=O; 
if qii2x= 'ms contin' then qii2x2a=O; 
if qii2x= 'theodur' then qii2x2a=O; 
if qii2x= '3tc' then qii2x2a=O; 
if qii2x= 'azt' then qii2x2a=O; 
if qii2x= 'd4t' then qii2x2a=O; 
if qii2x= 'ddc' then qii2x2a=O; 
if qii2x= 'ddi' then qii2x2a=O; 
if qii2x= 'epivir' then qii2x2a=O; 
if qii2x= 'zerit' then qii2x2a=O; 
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( if qii2x2a=O then qii2x14=.; 
if qii2x14=99 then qii2x2a=.; 
if qii2x2a=l then qii2x2a=24; 
if qii2x2a=2 then qii2x2a=36; 
if qii2x2a=3 then qii2x2a=45; 
if qii2x2a=4 then qii2x2a=90; 
if qii2x2a=5 then qii2x2a=l80; 
if qii2x2a=6 then qii2x2a=270; 
if qii2x2a=7 then qii2x2a=360; 
if qii2x2a=8 then qii2x2a=450; 
med2= qii2x14/qii2x2a; 
comp2=1-med2; 
percomp2=comp2 * l 00; 
if qii3x= 'acyclovir' then qii3x2a=O; 
if qii3x= 'bactrim' then qii3x2a=O; 
if qii3x= 'biaxin' then qii3x2a=O; 
if qii3x= 'clotrimazole' then qii3x2a=O; 
if qii3x= 'compazine' then qii3x2a=O; 
if qii3x= 'dapsone' then qii3x2a=O; 
if qii3x= 'diltiazem' then qii3x2a=O; 
if qii3x= 'fluconazole' then qii3x2a=O; 
if qii3x= 'mellaril' then qii3x2a=O; 
if qii3x= 'minocycline' then qii3x2a=O; 
if qii3x= 'motrin' then qii3x2a=O; 
if qii3x= 'oxandrin' then qii3x2a=O; 
if qii3x= 'vasotec' then qii3x2a=O; 
if qii3x= 'zantac' then qii3x2a=O; 
if qii3x= 'zovirax' then qii3x2a=O; 
if qiilx= 'azt' then qiilx2a=O; 
if qiilx= '3tc' then qiilx2a=O; 
if qii 1 x= 'd4t' then qii 1 x2a=O; 
if qiilx= 'epivir' then qiilx2a=O; 
if qii3x2a=O then qii3x 14=.; 
if qii3x14=99 then qii3x2a=.; 
if qii3x2a=l then qii3x2a=24; 
if qii3x2a=2 then qii3x2a=36; 
if qii3x2a=3 then qii3x2a=45; 
if qii3x2a=4 then qii3x2a=90; 
if qii3x2a=5 then qii3x2a=180; 
if qii3x2a=6 then qii3x2a=270; 
if qii3x2a=7 then qii3x2a=360; 
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( if qii3x2a=8 then qii3x2a=450; 
med3= qii3x14/qii3x2a; 
comp3=1-med3; 
percomp3=comp3*100; 
if percomp 1 =. then percomp 1 =0; 
if percomp2=. then percomp2=0; 
if percomp3=. then percomp3=0; 
totcomp= percomp 1 +percomp2+percomp3; 
ifpercompl=O and percomp2 NE 0 and percomp3 NE 0 then totcomp= totcomp/2; 
if percomp 1 NE 0 and percomp2= 0 and percomp3 NE 0 then totcomp= totcomp/2; 
ifpercompl NE 0 and percomp2 NE 0 and percomp3= 0 then totcomp=totcomp/2; 
ifpercompl NE 0 and percomp2 NE 0 and percomp3 NE 0 then totcomp=totcomp/3; 
if percomp 1 NE 0 and percomp2=0 and percomp3= 0 then totcomp= totcomp; 
if percomp 1 =O and percomp2 NE 0 and percomp3= 0 then totcomp= totcomp; 
if percomp 1 =O and percomp2=0 and percomp3 NE 0 then totcomp= totcomp; 
if totcomp=O then delete; 
compb=totcomp GE 95; 
/*PROGRAM TO CATEGORIZE INDEPENDENT VARIABLES*/ 
if qi4=1 then qi4=1 ; 
else if qi4=2 or qi4=3 or qi4=4 or qi4=5 or qi4=6 then qi4=0; 
if qi5=0 then qi5=.; 
if qi29= 1 or qi29=2 or qi29=3 or qi29=4 then qi29=1; 
if qi29=5 then qi29=2; 
if qi29=6 then qi29=3; 
if qi29=0 then qi29=.; 
if qi31 =0 then qi31 =.; 
else if qi31 = 1 or qi31 =2 then qi31 =O; 
else if qi31= 3 or qi31 =4 then qi31 =1; 
if qvi52= 0 or qvi52=l then qvi52=1; 
else if qvi52= 2 or qvi52=3 then qvi52=0; 
ifqil GE 24 andqil Lt 35 thenqil=l ; 
else if qil GE 35 and qil LE 41 then qil =2; 
elseifqil GT 41 thenqi1 =3; 
if qi5 LT 12 then qi5=0; 
else if qi5 GE 12 then qi5=1; 
if qi19=0 then qi19=.; 
if qi 19=.1 then qi 19=1; 
if qi 19=2 then qi 19=0; 
if qi19=3 then qi19=0; 
if qi19=4 then qi19=0; 
if qi19=5 then qi19=0; 
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sex=.; 
if qi2='m' then sex=l; 
else if qi2='f then sex=O; 
if qi7=1 then qi7=l; 
else if qi7=2 then qi7=0; 
if qi l 8a=l the qi l 8a=O; 
if qil8a=2 then qi18a=l; 
Mqil=.; 
if qi 1 =2 then Mqil =1; 
else if qi 1 =1 or qi 1 =3 then Mqi 1 =O; 
Hqil=.; 
if qi 1 =3 then Hqil =I; 
else if qi 1 =2 or qi 1 =1 then Hqi 1 =O; 
Mqi29=.; 
if qi29=2 then Mqi29=1; 
else if qi29=l or qi29=3 then Mqi29=0; 
Hqi29=.; 
if qi29=3 then Hqi29=1; 
else if qi29=1 or qi29=2 then Hqi29=0; 
/*PROGRAM TO MEASURE HRQoL *I 
if qi3=1 then qi3=5.0; 
if qi3=2 then qi3=4.4; 
if qi3=3 then qi3=3.4; 
if qi3=4 then qi3=2.0; 
if qi3=5 then qi3=1.0; 
if qi24=1 then qi24=6.0; 
if qi24=2 then qi24=5.4; 
if qi24=3 then qi24=4.2; 
if qi24=4 then qi24=3.1; 
if qi24=5 then qi24=2.2; 
if qi24=6 then qi24=1.0; 
if qi25=0 then qi25=.; 
if qi25=1 and qi24=99 then qi25=6.0; 
if qi25=2 and qi24=99 then qi25=4.75; 
if qi25=3 and qi24=99 then qi25=3.5; 
if qi25=4 and qi24=99 then qi25=2.25; 
if qi25=5 and qi24=99 then qi25=1.0; 
if qi25=1 and qi24=1 then qi25=6.0; 
if qi25=1 and qi24 GE 2 and qi24 LE 6 then qi25=5; 
if qi25=2 and qi24 GE 1 and qi24 LE 6 then qi25=4; 
if qi25=3 and qi24 GE 1 and qi24 LE 6 then qi25=3; 
if qi25=4 and qi24 GE l and qi24 LE 6 then qi25=2; 
if qi25=5 and qi24 GE 1 and qi24 LE 6 then qi25=1; 
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if qi26=0 then qi26=6; 
if qi26=l then qi26=5; 
if qi26=2 then qi26=4; 
if qi26 GE 3 and qi26 LE 5 then qi26=3; 
if qi26 GE 6 and qi26 LE 7 then qi26=2; 
if qi26 GE 7 and qi26 LE 28 then qi26=1; 
if qi26=99 then qi26=.; 
if qi28a=O then qi28a=99; 
if qi28b=O then qi28b=99; 
if qi28c=O then qi28c=99; 
if qi28d=O then qi28d=99; 
if qi28e=O then qi28e=99; 
if qi28f=O then qi28f=99; 
if qi28g=O then qi28g=99; 
if qi28h=O then qi28h=99; 
if qi28i=O then qi28i=99; 
if qi28g=l then qi28g=6; 
if qi28g=2 then qi28g=5; 
if qi28g=3 then qi28g=4; 
if qi28g=4 then qi28g=3; 
if qi28g=5 then qi28g=2; 
if qi28g=6 then qi28g=l ; 
if qi28i=l then qi28i=6; 
if qi28i=2 then qi28i=5; 
if qi28i=3 then qi28i=4; 
if qi28i=4 then qi28i=3; 
if qi28i=5 then qi28i=2; 
if qi28i=6 then qi28i=l ; 
if qi28b=l then qi28b=6; 
if qi28b=2 then qi28b=5; 
if qi28b=3 then qi28b=4; 
if qi28b=4 then qi28b=3; 
if qi28b=5 then qi28b=2; 
if qi28b=6 then qi28b=l ; 
if qi28c=l then qi28c=6; 
if qi28c=2 then qi28c=5; 
if qi28c=3 then qi28c=4; 
if qi28c=4 then qi28c=3; 
if qi28c=5 then qi28c=2; 
if qi28c=6 then qi28c=l ; 
if qi28f=l then qi28f=6; 
if qi28f=2 then qi28f=5; 
if qi28f=3 then qi28f=4; 
if qi28f=4 then qi28f=3; 
if qi28f=5 then qi28f=2; 
if qi28f=6 then qi28f=l ; 
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GHr=qi3; 
BPr=qi24+qi25; 
RPr=qi26; 
Vrl =qi28a+qi28e+qi28g+qi28i; 
ifVrl GE 117 then Vrl=O; 
MHrl =qi28b+qi28c+qi28d+qi28f+qi28h; 
ifMHrl GE 123 then MHrl=O; 
data rakesh2; 
set rakesh 1 ; 
if qi28a=99 then qi28a=(qi28e+qi28g+qi28i)/3; 
if qi28b=99 then qi28b=(qi28c+qi28d+qi28f+qi28h)/4; 
if qi28c=99 then qi28c=(qi28b+qi28d+qi28f+qi28h)/4;; 
if qi28d=99 then qi28d=(qi28b+qi28c+qi28f+qi28h)/4; 
if qi28e=99 then qi28e=( qi28a+qi28g+qi28i)/3 ; 
if qi28f=99 then qi28f=(qi28b+qi28c+qi28d+qi28h)/4; 
if qi28g=99 then qi28g=(qi28a+qi28e+qi28i/3); 
if qi28h=99 then qi28h=(qi28b+qi28c+qi28d+qi28f)/4; 
if qi28i=99 then qi28i=(qi28a+qi28e+qi28g/3); 
Vr=qi28a+qi28e+qi28g+qi28i; 
ifVrl=O then Vr=.; 
MHr=qi28b+qi28c+qi28d+qi28f+qi28h; 
ifMHrl=O then MHr=.; 
GR=(GHr-1)/4*100; 
BP=(BPr-2)/10*100; 
RP=(RPr-l )/5*100; 
V=(Vr-4)/20*100; 
MH=(MRr-5)/25*100; 
if GR LE 25 then GR=O; 
else ifGR GT 25 then GR=l; 
if BP LT 42 then BP=O; 
else if BP GE 42 then BP=l ; 
ifV LE 20 then V=O; 
else ifV GT 20 then V=l ; 
ifMH LT 36 then MH=O; 
else ifMH GE 36 then MH=l ; 
keep Mqil Rqil sex qi4 qi5 qi7 qi18a qi19 Mqi29 Rqi29 qi31 qvi52 GR BP V MH 
compa compb; 
I* proc freq; 
proc univariate nonnal plot; 
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proc freq; 
tables MH*qil/all; 
tables MH*sex/all; 
tables MH*qi4/all; 
tables MH*qi5/all; 
tables MH*qi7/a11; 
tables MH*qi l 8a/all; 
tables MH*qil9/all; 
tables MH*qi29/all; 
tables MH*qi3 l/all;*/ 
proc logistic descending; 
model compb = MH sex qi31 /ctable pprob=(O to 1 by .1 ) lackfit 
risklimits; 
run; 
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/*SAS PROGRAM TO MEASURE ADHERENCE USING MEDICATION 
ADHERENCE SCALE FOR PATIENTS ON ANTI-RETROVIRAL DRUGS*/ 
options nocenter linesize=72; 
libname rakesh 'c:\ Windows\Desktop\rakesh'; 
data rakesh 1; 
set rakesh.hivsurv; 
if qiilx4=0 then qiilx4=99; 
if qiilx5=0 then qiilx5=99; 
if qiilx6=0 then qiilx6=99; 
if qiilx7=0 then qiilx7=99; 
if qiilx8=0 then qiilx8=99; 
if qiilx9=0 then qiilx9=99; 
if qii2x4=0 then qii2x4=99; 
if qii2x5=0 then qii2x5=99; 
if qii2x6=0 then qii2x6=99; 
if qii2x7=0 then qii2x7=99; 
if qii2x8=0 then qii2x8=99; 
if qii2x9=0 then qii2x9=99; 
if qii3x4=0 then qii3x4=99; 
if qii3x5=0 then qii3x5=99; 
if qii3x6=0 then qii3x6=99; 
if qii3x7=0 then qii3x7=99; 
if qii3x8=0 then qii3x8=99; 
if qii3x9=0 then qii3x9=99; 
maslx= qii lx4+qiilx5+qiilx6+qii lx7+qiilx8+qii lx9; 
ifmasl GE 109 then masl=O; 
mas2x= qii2x4+qii2x5+qii2x6+qii2x7+qii2x8+qii2x9; 
if mas2x GE 109 then mas2=0; 
mas3x= qii3x4+qii3x5+qii3x6+qii3x7+qii3x8+qii3x9; 
if mas3x GE 109 then mas3=0; 
data rakesh2; 
set rakesh 1; 
if qiilx4=99 then qiilx4=0; 
if qiilx5=99 then qiilx5=0; 
if qiilx6=99 then qiilx6=0; 
if qiilx7=99 then qiilx7=0; 
if qiilx8=99 then qiilx8=0; 
if qiilx9=99 then qiilx9=0; 
masl =qii lx4+qiilx5+qiilx6+qii lx7+qiilx8+qiilx9; 
ifmaslx=O then masl=O; 
if qii2x4=99 then qii2x4=0; 
81 
if qii2x5=99 then qii2x5=0; 
if qii2x6=99 then qii2x6=0; 
if qii2x7=99 then qii2x7=0; 
if qii2x8=99 then qii2x8=0; 
if qii2x9=99 then qii2x9=0; 
mas2=qii2x4+qii2x5+qii2x6+qii2x7+qii2x8+qii2x9; 
if mas2x=O then mas2=0; 
if qii3x4=99 then qii3x4=0; 
if qii3x5=99 then qii3x5=0; 
if qii3x6=99 then qii3x6=0; 
if qii3x7=99 then qii3x7=0; 
if qii3x8=99 then qii3x8=0; 
if qii3x9=99 then qii3x9=0; 
mas3=qii3x4+qii3x5+qii3x6+qii3x7+qii3x8+qii3x9; 
if mas3x=O then mas3=0; 
if qii 1 x= 'bachim' then mas 1 =O; 
if qiilx= 'acyclovir' then masl =O; 
if qii lx= 'pentamidine' then masl =O; 
if qii lx= 'zoloft' then mas 1 =O; 
if qiilx= 'crixivan' then masl=O; 
if qiilx= 'ritonavir' then masl =O; 
if qii 1 x= 'saquinavir' then mas 1 =O; 
if qii2x= 'bactrim' then mas2=0; 
if qii2x= 'dapsone' then mas2=0; 
if qii2x= 'leucovorin' then mas2=0; 
if qii2x= 'ms contin' then mas2=0; 
if qii2x= 'theodur' then mas2=0; 
if qii2x= 'crixivan' then mas2=0; 
if qii2x= 'saquinavir' then mas2=0; 
if qii2x= 'indinavir' then mas2=0; 
if qii2x= 'ritonavir' then mas2=0; 
if qii3x= 'acyclovir' then mas3=0; 
if qii3x= 'bactrim' then mas3=0; 
if qii3x= 'biaxin' then mas3=0; 
if qii3x= 'clotrimazole' then mas3=0; 
if qii3x= 'compazine' then mas3=0; 
if qii3x= 'dapsone' then mas3=0; 
if qii3x= 'diltiazem' then mas3=0; 
if qii3x= 'fluconazole' then mas3=0; 
if qii3x= 'mellaril' then mas3=0; 
if qii3x= 'minocycline' then mas3=0; 
if qii3x= 'motrin' then mas3=0; 
if qii3x= 'oxandrin' then mas3=0; 
if qii3x= 'vasotec' then mas3=0; 
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if qii3x= 'zantac' then mas3=0; 
if qii3x= 'zovirax' then mas3=0; 
if qii3x= 'crixivan' then mas3=0; 
if qii3x= 'indinavir' then mas3=0; 
if qii3x= 'invirase' then mas3=0; 
if qii3x= 'norvir' then mas3=0; 
if qii3x= 'ritonavir' then mas3=0; 
if qii3x= 'saquinavir' then mas3=0; 
totmas=mas 1 +mas2+mas3 ; 
if mas 1 NE 0 and mas2 NE 0 and mas3 NE 0 then totmas= totmas/3; 
if mas 1 NE 0 and mas2= 0 and mas3 NE 0 then totmas= totmas/2; 
ifmasl=O and mas2 NE 0 and mas3 NE 0 then totmas= totmas/2; 
if mas 1 NE 0 and mas2 NE 0 and mas3=0 then totmas= totmas/2; 
if mas 1 NE 0 and mas2=0 and mas3=0 then totmas=totmas; 
if mas 1 =0 and mas2 NE 0 and mas3=0 then totmas=totmas; 
if mas 1 =O and mas2=0 and mas3 NE 0 then totmas=totmas; 
if totmas LT 6 then delete; 
totmas 1 =12-totmas; 
iftotmasl = 6 then totmasl=l ; 
else if totmasl LT 6 then totmasl = O; 
/*PROGRAM TO CATEGORIZE INDEPENDENT VARIABLES*/ 
if qi4=1 then qi4=1; 
else if qi4=2 or qi4=3 or qi4=4 or qi4=5 or qi4=6 then qi4=0; 
if qi5=0 then qi5=.; 
if qi29= 1 or qi29=2 or qi29=3 or qi29=4 then qi29=1; 
if qi29=5 then qi29=2; 
if qi29=6 then qi29=3; 
if qi29=0 then qi29=.; 
if qi31 =O then qi31 =.; 
else if qi31 = 1 or qi31 =2 then qi31 =0; 
else if qi31 = 3 or qi31 =4 then qi31 =1; 
if qvi52= 0 or qvi52=1 then qvi52=1; 
else if qvi52= 2 or qvi52=3 then qvi52=0; 
if qil GE 24 and qil Lt 35 then qil=l ; 
elseifqil GE 35 andqil LE 41 thenqil =2; 
elseifqil GT 41 thenqi1=3; 
if qi5 LT 12 then qi5=0; 
else if qi5 GE 12 then qi5=1; 
ifqi19=0 then qi19=.; 
if qi 19=1 then qi 19=1; 
if qil9=2 then qil9=0; 
if qi19=3 then qi19=0; 
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( if qi19=4 then qi19=0; 
if qi19=5 then qi19=0; 
if qi2=0 then qi2=.; 
sex=.; 
if qi2='f then sex=O; 
if qi2='m' then sex=l; 
if qi7=1 then qi7=1; 
else if qi7=2 then qi7=0; 
if qi 18a= 1 then qi 18a=O; 
if qi18a=2 then qi18a=l; 
Mqil=.; 
if qil =2 then Mqil =1; 
else if qi 1 =1 or qi 1 =3 then Mqi 1 =0; 
Hqil=.; 
ifqi1=3 thenHqil=l; 
else if qil =2 or qi 1 =1 then Hqil =O; 
Mqi29=.; 
if qi29=2 then Mqi29=1; 
else if qi29=1 or qi29=3 then Mqi29=0; 
Hqi29=.; 
if qi29=3 then Hqi29=1; 
else if qi29=l or qi29=2 then Hqi29=0; 
/*PROGRAM TO MEASURE HRQoL */ 
if qi3=1 then qi3=5.0; 
if qi3=2 then qi3=4.4; 
if qi3=3 then qi3=3.4; 
if qi3=4 then qi3=2.0; 
if qi3=5 then qi3=1.0; 
if qi24=1 then qi24=6.0; 
if qi24=2 then qi24=5.4; 
if qi24=3 then qi24=4.2; 
ifqi24=4 then qi24=3.l; 
if qi24=5 then qi24=2.2; 
if qi24=6 then qi24=1.0; 
if qi25=0 then qi25=.; 
if qi25=1 and qi24=99 then qi25=6.0; 
if qi25=2 and qi24=99 then qi25=4.75; 
if qi25=3 and qi24=99 then qi25=3.5; 
if qi25=4 and qi24=99 then qi25=2.25; 
if qi25=5 and qi24=99 then qi25=1.0; 
if qi25=1 and qi24=1 then qi25=6.0; 
if qi25=1 and qi24 GE 2 and qi24 LE 6 then qi25=5; 
if qi25=2 and qi24 GE 1 and qi24 LE 6 then qi25=4; 
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if qi25=3 and qi24 GE 1 and qi24 LE 6 then qi25=3; 
if qi25=4 and qi24 GE 1 and qi24 LE 6 then qi25=2; 
if qi25=5 and qi24 GE 1 and qi24 LE 6 then qi25=1; 
if qi26=0 then qi26=6; 
if qi26=1 then qi26=5; 
if qi26=2 then qi26=4; 
if qi26 GE 3 and qi26 LE 5 then qi26=3; 
if qi26 GE 6 and qi26 LE 7 then qi26=2; 
if qi26 GE 7 and qi26 LE 28 then qi26=1; 
if qi26=99 then qi26=.; 
if qi28a=O then qi28a=99; 
if qi28b=O then qi28b=99; 
if qi28c=O then qi28c=99; 
if qi28d=O then qi28d=99; 
if qi28e=O then qi28e=99; 
if qi28f=O then qi28f=99; 
if qi28g=O then qi28g=99; 
if qi28h=O then qi28h=99; 
if qi28i=O then qi28i=99; 
if qi28g=l then qi28g=6; 
if qi28g=2 then qi28g=5; 
if qi28g=3 then qi28g=4; 
if qi28g=4 then qi28g=3; 
if qi28g=5 then qi28g=2; 
if qi28g=6 then qi28g=l; 
if qi28i=l then qi28i=6; 
if qi28i=2 then qi28i=5; 
if qi28i=3 then qi28i=4; 
if qi28i=4 then qi28i=3; 
if qi28i=5 then qi28i=2; 
if qi28i=6 then qi28i=l; 
if qi28b=l then qi28b=6; 
if qi28b=2 then qi28b=5; 
if qi28b=3 then qi28b=4; 
if qi28b=4 then qi28b=3; 
if qi28b=5 then qi28b=2; 
if qi28b=6 then qi28b=l; 
if qi28c=l then qi28c=6; 
if qi28c=2 then qi28c=5; 
if qi28c=3 then qi28c=4; 
if qi28c=4 then qi28c=3; 
if qi28c=5 then qi28c=2; 
if qi28c=6 then qi28c=l; 
if qi28f=l then qi28f=6; 
if qi28f=2 then qi28f=S; 
if qi28f=3 then qi28f=4; 
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( 
if qi28f=4 then qi28f=3; 
if qi28f=S then qi28f=2; 
if qi28f=6 then qi28f=l; 
GHr=qi3; 
BPr=qi24+qi25; 
RPr=qi26; 
Vrl =qi28a+qi28e+qi28g+qi28i; 
ifVrl GE 117 then Vrl=O; 
MHrl =qi28b+qi28c+qi28d+qi28f+qi28h; 
if MHrl GE 123 then MHrl =O; 
data rakesh3; 
set rakesh2; 
if qi28a=99 then qi28a=(qi28e+qi28g+qi28i)/3; 
if qi28b=99 then qi28b=(qi28c+qi28d+qi28f+qi28h)/4; 
if qi28c=99 then qi28c=(qi28b+qi28d+qi28f+qi28h)/4;; 
if qi28d=99 then qi28d=(qi28b+qi28c+qi28f+qi28h)/4; 
if qi28e=99 then qi28e=(qi28a+qi28g+qi28i)/3; 
if qi28f=99 then qi28f=(qi28b+qi28c+qi28d+qi28h)/4; 
if qi28g=99 then qi28g=(qi28a+qi28e+qi28i/3); 
if qi28h=99 then qi28h=( qi28b+qi28c+qi28d+qi28f)/4; 
if qi28i=99 then qi28i=(qi28a+qi28e+qi28g/3); 
V r=qi28a+qi28e+q i28 g+qi28i; 
ifVrl=O then Vr=.; 
MHr=qi28b+qi28c+qi28d+qi28f+qi28h; 
if MHr 1 =O then MHr=.; 
GH=(GHr-1)/4*100; 
BP=(BPr-2)/1O*l00; 
RP=(RPr-1)/5*100; 
V=(Vr-4)/20* 100; 
MH=(MHr-5)/25*100; 
ifGH LT 60 then GH=O; 
else ifGH GE 60 then GH=l; 
if BP LT 42 then BP=O; 
else if BP GE 42 then BP=l; 
if V LE 20 then V=O; 
else ifV GT 20 then V=l; 
ifMH LT 32 then MH=O; 
else if MH GE 32 then MH=l; 
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keep Mqil Hqil sex qi4 qi5 qi7 qi l 8a qi l9 Mqi29 Hqi29 qi3 l qvi52 GH BP V MH 
totmasl; 
/*proc freq; 
proc univariate nonnal plot; 
proc freq; 
tables MH*qi l/all; 
tables MH*sex/all; 
tables MH*qi4/all; 
tables MH*qi5/al1; 
tables MH*qi7/all; 
tables MH*qil8a/all; 
tables MH*qi 19/all; 
tables MH*qi29/all; 
tables MH*qi31 /all;*/ 
proc logistic descending; 
model totmasl = MH Mqil Hqil qi7 qil9 qi31 /ctable pprob=(O to 1 by .1) lackfit 
risklirnits; 
run; 
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/*SAS PROGRAM TO MEASURE ADHERENCE USING MEDICATION 
ADHERENCE SCALE FOR PATIENTS TAKING PROTEASE INHIBITORS*/ 
options nocenter linesize=72; 
libname rakesh 'c:\ Windows\Desktop\rakesh'; 
data rakeshl; 
set rakesh.hivsurv; 
if qiilx4=0 then qiilx4=99; 
if qiilx5=0 then qiilx5=99; 
if qiilx6=0 then qiilx6=99; 
if qiilx7=0 then qiilx7=99; 
if qiilx8=0 then qiilx8=99; 
if qii 1 x9=0 then qii 1 x9=99; 
if qii2x4=0 then qii2x4=99; 
if qii2x5=0 then qii2x5=99; 
if qii2x6=0 then qii2x6=99; 
if qii2x7=0 then qii2x7=99; 
if qii2x8=0 then qii2x8=99; 
if qii2x9=0 then qii2x9=99; 
if qii3x4=0 then qii3x4=99; 
if qii3x5=0 then qii3x5=99; 
if qii3x6=0 then qii3x6=99; 
if qii3x7=0 then qii3x7=99; 
if qii3x8=0 then qii3x8=99; 
if qii3x9=0 then qii3x9=99; 
maslx= qiilx4+qii lx5+qiilx6+qiilx7+qii lx8+qiilx9; 
if mas 1 x GE 109 then mas 1 =O; 
mas2x= qii2x4+qii2x5+qii2x6+qii2x7+qii2x8+qii2x9; 
if mas2x GE 109 then mas2=0; 
mas3x= qii3x4+qii3x5+qii3x6+qii3x7+qii3x8+qii3x9; 
ifmas3x GE 109 then mas3=0; 
data rakesh2; 
set rakesh 1; 
if qiilx4=99 then qiilx4=0; 
if qii 1 x5=99 then qii 1 x5=0; 
if qii 1 x6=99 then qii 1 x6=0; 
if qii 1 x7=99 then qii 1 x7=0; 
if qiilx8=99 then qiilx8=0; 
if qiilx9=99 then qiilx9=0; 
masl =qii lx4+qii lx5+qiilx6+qii lx7+qii lx8+qii lx9; 
ifmaslx=O then masl=O; 
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if qii2x4=99 then qii2x4=0; 
if qii2x5=99 then qii2x5=0; 
if qii2x6=99 then qii2x6=0; 
if qii2x7=99 then qii2x7=0; 
if qii2x8=99 then qii2x8=0; 
if qii2x9=99 then qii2x9=0; 
mas2=qii2x4+qii2x5+qii2x6+qii2x7+qii2x8+qii2x9; 
if mas2x=O then mas2=0; 
if qii3x4=99 then qii3x4=0; 
if qii3x5=99 then qii3x5=0; 
if qii3x6=99 then qii3x6=0; 
if qii3x7=99 then qii3x7=0; 
if qii3x8=99 then qii3x8=0; 
if qii3x9=99 then qii3x9=0; 
mas3=qii3x4+qii3x5+qii3x6+qii3x7+qii3x8+qii3x9; 
if mas3x=O then mas3=0; 
if qii 1 x= 'bactrim' then mas 1 =O; 
if qiilx= 'acyclovir' then masl =O; 
if qii 1 x= 'pentamidine' then mas 1 =O; 
if qiilx= 'zoloft' then masl=O; 
if qii lx= '3tc' then masl =0; 
if qiilx= 'azt' then masl=O; 
if qiilx= 'd4t' then masl =O; 
ifqiilx= 'ddi' then masl=O; 
if qii 1 x= 'ddc' then mas 1 =O; 
if qiilx= 'epivir' then masl=O; 
if qiilx= 'zerit' then masl=O; 
if qii2x= 'bactrim' then mas2=0; 
if qii2x= 'dapsone' then mas2=0; 
if qii2x= 'leucovorin' then mas2=0; 
if qii2x= 'ms contin' then mas2=0; 
if qii2x= 'theodur' then mas2=0; 
if qii2x= '3tc' then mas2=0; 
if qii2x= 'azt' then mas2=0; 
if qii2x= 'd4t' then mas2=0; 
if qii2x= 'ddc' then mas2=0; 
if qiilx= 'ddi' then masl=O; 
if qiilx= 'epivir' then masl=O; 
if qiilx= 'zerit' then masl=O; 
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if qii3x= 'acyclovir' then mas3=0; 
if qii3x= 'bactrim' then mas3=0; 
if qii3x= 'biaxin' then mas3=0; 
if qii3x= 'clotrimazole' then mas3=0; 
if qii3x= 'compazine' then mas3=0; 
if qii3x= 'dapsone' then mas3=0; 
if qii3x= 'diltiazem' then mas3=0; 
if qii3x= 'fluconazole' then mas3=0; 
if qii3x= 'mellaril' then mas3=0; 
if qii3x= 'minocycline' then mas3=0; 
if qii3x= 'motrin' then mas3=0; 
if qii3x= 'oxandrin' then mas3=0; 
if qii3x= 'vasotec' then mas3=0; 
if qii3x= 'zantac' then mas3=0; 
if qii3x= 'zovirax' then mas3=0; 
if qii3x= '3tc' then mas3=0; 
if qii3x= 'azt' then mas3=0; 
if qii3x= 'd4t' then mas3=0; 
if qii3x= 'epivir' then mas3=0; 
totmas=mas 1 +mas2+mas3; 
ifmasl NE 0 and mas2 NE 0 and mas3 NE 0 then totmas= totmas/3; 
ifmasl NE 0 and mas2= 0 and mas3 NE 0 then totmas= totmas/2; 
ifmasl=O and mas2 NE 0 and mas3 NE 0 then totmas= totmas/2; 
ifmasl NE 0 and mas2 NE 0 and mas3=0 then totmas= totmas/2; 
if mas 1 NE 0 and mas2=0 and mas3=0 then totmas=totmas; 
if mas 1 =O and mas2 NE 0 and mas3=0 then totmas=totmas; 
if mas 1 =O and mas2=0 and mas3 NE 0 then totmas=totmas; 
if totmas LT 6 then delete; 
totmas 1 = 12-totmas; 
if totmas 1 = 6 then totmas 1 =1; 
else if totmas 1 LT 6 then totmas 1 = O; 
/*PROGRAM TO CATEGORIZE INDEPENDENT VARIABLES*/ 
if qi4=1 then qi4=1; 
else if qi4=2 or qi4=3 or qi4=4 or qi4=5 or qi4=6 then qi4=0; 
if qi5=0 then qi5=.; 
if qi29= 1 or qi29=2 or qi29=3 or qi29=4 then qi29=1; 
if qi29=5 then qi29=2; 
if qi29=6 then qi29=3; 
if qi29=0 then qi29=.; 
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if qi3 l =0 then qi3 l =.; 
else if qi31 = 1 or qi3 l =2 then qi3 l =O; 
else if qi31 = 3 or qi3 l =4 then qi3 l =1; 
if qvi52= 0 or qvi52=1 then qvi52=1; 
else if qvi52= 2 or qvi52=3 then qvi52=0; 
if qi 1 GE 24 and qi 1 Lt 35 then qi 1 =1; 
else if qil GE 35 and qil LE 41 then qil=2; 
elseifqil GT41 thenqi1=3; 
if qi5 LT 12 then qi5=0; 
else if qi5 GE 12 then qi5=1; 
if qil9=0 then qil9=.; 
if qi 19=1 then qi 19=1; 
if qil9=2 then qil9=0; 
if qi 19=3 then qi 19=0; 
if qil9=4 then qi19=0; 
if qi19=5 then qil9=0; 
if qi2=0 then qi2=.; 
sex=.; 
if qi2='f then sex=O; 
if qi2='m' then sex=l; 
if qi7=1 then qi7=1; 
else if qi7=2 then qi7=0; 
if qil8a=l then qil8a=O; 
if qi l 8a=2 then qi l 8a=l; 
Mqil=.; 
ifqil=2 thenMqil=l; 
else if qi 1 =1 or qi 1 =3 then Mqi 1 =O; 
Hqil=.; 
if qil=3 then Hqil=l; 
else if qi 1 =2 or qi 1 =l then Hqi 1 =O; 
Mqi29=.; 
if qi29=2 then Mqi29=1; 
else if qi29=1 or qi29=3 then Mqi29=0; 
Hqi29=.; 
if qi29=3 then Hqi29=1; 
else if qi29=1 or qi29=2 then Hqi29=0; 
/*PROGRAM TO MEASURE HRQoL *I 
if qi3=1 then qi3=5.0; 
if qi3=2 then qi3=4.4; 
if qi3=3 then qi3=3.4; 
if qi3=4 then qi3=2.0; 
if qi3=5 then qi3=1.0; 
if qi24=1 then qi24=6.0; 
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if qi24=2 then qi24=5.4; 
if qi24=3 then qi24=4.2; 
if qi24=4 then qi24=3.1; 
if qi24=5 then qi24=2.2; 
if qi24=6 then qi24=1.0; 
if qi25=0 then qi25=.; 
if qi25=1 and qi24=99 then qi25=6.0; 
if qi25=2 and qi24=99 then qi25=4. 75; 
if qi25=3 and qi24=99 then qi25=3.5; 
if qi25=4 and qi24=99 then qi25=2.25; 
if qi25=5 and qi24=99 then qi25=1.0; 
if qi25=1 and qi24=1 then qi25=6.0; 
if qi25=1 and qi24 GE 2 and qi24 LE 6 then qi25=5; 
if qi25=2 and qi24 GE 1 and qi24 LE 6 then qi25=4; 
if qi25=3 and qi24 GE 1 and qi24 LE 6 then qi25=3; 
if qi25=4 and qi24 GE 1 and qi24 LE 6 then qi25=2; 
if qi25=5 and qi24 GE 1 and qi24 LE 6 then qi25=1; 
if qi26=0 then qi26=6; 
if qi26=1 then qi26=5; 
if qi26=2 then qi26=4; 
if qi26 GE 3 and qi26 LE 5 then qi26=3; 
if qi26 GE 6 and qi26 LE 7 then qi26=2; 
if qi26 GE 7 and qi26 LE 28 then qi26=1; 
if qi26=99 then qi26=.; 
if qi28a=O then qi28a=99; 
if qi28b=O then qi28b=99; 
if qi28c=O then qi28c=99; 
if qi28d=O then qi28d=99; 
if qi28e=O then qi28e=99; 
if qi28f=O then qi28f=99; 
if qi28g=O then qi28g=99; 
if qi28h=O then qi28h=99; 
if qi28i=O then qi28i=99; 
if qi28g=l then qi28g=6; 
if qi28g=2 then qi28g=5; 
if qi28g=3 then qi28g=4; 
if qi28g=4 then qi28g=3; 
if qi28g=5 then qi28g=2; 
if qi28g=6 then qi28g=l; 
if qi28i=l then qi28i=6; 
if qi28i=2 then qi28i=5; 
if qi28i=3 then qi28i=4; 
if qi28i=4 then qi28i=3; 
if qi28i=5 then qi28i=2; 
if qi28i=6 then qi28i=l; 
if qi28b=l then qi28b=6; 
92 
if qi28b=2 then qi28b=S; 
if qi28b=3 then qi28b=4; 
if qi28b=4 then qi28b=3; 
if qi28b=S then qi28b=2; 
if qi28b=6 then qi28b=l; 
if qi28c=l then qi28c=6; 
if qi28c=2 then qi28c=S; 
if qi28c=3 then qi28c=4; 
if qi28c=4 then qi28c=3; 
if qi28c=S then qi28c=2; 
if qi28c=6 then qi28c=l; 
if qi28f=l then qi28f=6; 
if qi28f=2 then qi28f=S; 
if qi28f=3 then qi28f=4; 
if qi28f=4 then qi28f=3; 
if qi28f=S then qi28f=2; 
if qi28f=6 then qi28f=l; 
GHr=qi3; 
BPr=qi24+qi25; 
RPr=qi26; 
Vrl =qi28a+qi28e+qi28g+qi28i; 
if Vrl GE 117 then Vrl =O; 
MHrl =qi28b+qi28c+qi28d+qi28f+qi28h; 
ifMHrl GE 123 then MHrl=O; 
data rakesh3; 
set rakesh2; 
if qi28a=99 then qi28a=(qi28e+qi28g+qi28i)/3; 
if qi28b=99 then qi28b=(qi28c+qi28d+qi28f+qi28h)/4; 
if qi28c=99 then qi28c=(qi28b+qi28d+qi28f+qi28h)/4;; 
if qi28d=99 then qi28d=(qi28b+qi28c+qi28f+qi28h)/4; 
if qi28e=99 then qi28e=(qi28a+qi28g+qi28i)/3; 
if qi28f=99 then qi28f=(qi28b+qi28c+qi28d+qi28h)/4; 
if qi28g=99 then qi28g=(qi28a+qi28e+qi28i/3); 
if qi28h=99 then qi28h=(qi28b+qi28c+qi28d+qi28f)/4; 
if qi28i=99 then qi28i=(qi28a+qi28e+qi28g/3); 
V r=qi28a+qi28e+q i28 g+q i28i; 
ifVrl=O then Vr=.; 
MHr=qi28b+qi28c+qi28d+qi28f+qi28h; 
ifMHrl=O thenMHr=.; 
GH=(GHr-1)/4*100; 
93 
BP=(BPr-2)/1O*l00; 
RP=(RPr-1)/5*100; 
V=(Vr-4)/20*100; 
MH=(MHr-5)/25*100; 
ifGH LE 25 then GH=O; 
else if GH GT 25 then GH=l; 
if BP LT 42 then BP=O; 
else if BP GE 42 then BP=l; 
ifV LE 20 then V=O; 
else ifV GT 20 then V=l ; 
ifMH LT 36 then MH=O; 
else ifMH GE 36 then MH=l; 
keep Mqil Hqil sex qi4 qi5 qi7 qi18a qi19 Mqi29 Hqi29 qi31 qvi52 GH BP V MH 
totmasl ; 
/*proc freq; 
proc univariate normal plot; 
proc freq; 
tables MH*qil /all; 
tables MH*sex/all; 
tables MH*qi4/all; 
tables MH*qi5/all ; 
tables MH*qi7/all; 
tables MH*qi18a/a11; 
tables MH*qil9/al1; 
tables MH*qi29/all; 
tables MH*qi31 /a11;* / 
proc logistic descending; 
model totmasl = MH Mqil Hqil qi4 qi5 qi19 qi31 /ctable pprob=(O to l by .1 ) lackfit 
risklimits; 
run; 
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